

In order to avoid security-related warning messages when switching to secured connection, you may want either to:

- confirm the exception on the next page, or
- import our [CA key](#) in your web browser

Click [here](#) to proceed.

[SwissDrugDesign](#)

[SwissDock](#)

[SwissParam](#)

[SwissSidechain](#)

[SwissBioisostere](#)

[SwissTargetPrediction](#)

[SwissADME](#)

[SwissSimilarity](#)

[About us](#)

[Swiss Institute of Bioinformatics](#)

SwissADME

- [Terms of Use](#)
- [Help](#)
- [FAQ](#)
- [Home](#)


This website allows you to compute physicochemical descriptors as well as to predict ADME parameters, pharmacokinetic properties, druglike nature and medicinal chemistry friendliness of one or multiple small molecules to support drug discovery.

The main article describing the web service and its underlying methodologies is [SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. *Sci. Rep.* \(2017\) 7:42717.](#)

For details about development and validation of iLOG, please refer to this article: [iLOGP: a simple, robust, and efficient description of n-octanol/water partition coefficient for drug design using the GB/SA approach. *J. Chem. Inf. Model.* \(2014\) 54\(12\):3284-3301.](#)

For details about development and validation of the BOILED-Egg, please refer to this article: [A BOILED-Egg to predict gastrointestinal absorption and brain penetration of small molecules. *ChemMedChem* \(2016\) 11\(11\):1117-1121.](#)

Developed and maintained by the [Molecular Modeling Group](#) of the SIB | Swiss Institute of Bioinformatics.



Enter a list of SMILES here:

```
NCC(=O)N[C@@H]1CONC1=O
NCC(=O)N[C@H]1CONC1=O
FC([C@@H])([C@H](C(=O)O)N)O)F
FC([C@H])([C@H](C(=O)O)N)O)F
FC([C@@H])([C@H](C(=O)O)N)O)F
N[C@H](C(=O)O)[C@@H](c1cnco1)O
FC([C@H])([C@H](C(=O)O)N)O)F
N[C@H](C(=O)O)[C@H](c1cnco1)O
OC(=O)[C@H]([C@H](C(=O)N)F)N
OC(=O)[C@@H]([C@H](C(=O)N)F)N
C1C[C@H]([C@H](C(=O)O)N)O
OC(=O)[C@H]([C@H](C(=O)N)F)N
N[C@H](C(=O)O)[C@H](c1cnco1)O
N[C@H](C(=O)O)[C@H](c1cnco1)O
OC(=O)[C@H]([C@H](C(=O)N)F)N
N[C@H]1CON(C1=O)CCCO
NC1CON(C1=O)CCCO
OC(=O)[C@H](C(=C(F)F)F)N
OC(=O)C[C@H]1ONC(=O)[C@H]1N
OC(=O)C[C@H]1ONC(=O)[C@H]1N
```

Fill with an example

Clear

Run!

Show BOILED-Egg

Retrieve data: POWERED BY ChemAxon

Molecule 1





Log *S* (ESOL)

Water Solubility

0.74

[ESOL: Topological method implemented from](#)



SMILES NCC(=O)N[C@@H]1CONC1=O

Physicochemical Properties

Formula	C5H9N3O3
Molecular weight	159.14 g/mol
Num. heavy atoms	11
Num. arom. heavy atoms	0
Fraction Csp3	0.60
Num. rotatable bonds	3
Num. H-bond acceptors	4
Num. H-bond donors	3
Molar Refractivity	37.75
TPSA	

Topological Polar Surface Area:
Calculated from
[Ertl P. et al. 2000 J. Med. Chem.](#)

93.45 Å²

Log $P_{o/w}$ (iLOGP)

iLOGP: in-house physics-based method implemented from
[Daina A et al. 2014 J. Chem. Inf. Model.](#)

0.33

Log $P_{o/w}$ (XLOGP3)

XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

-2.17

Log $P_{o/w}$ (WLOGP)

WLOGP: Atomistic method implemented from
[Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.](#)

-2.89

Log $P_{o/w}$ (MLOGP)

MLOGP: Topological method implemented from
[Moriguchi I. et al. 1992 Chem. Pharm. Bull.](#)
[Moriguchi I. et al. 1994 Chem. Pharm. Bull.](#)

-2.17

[Delaney JS. 2004 J. Chem. Inf. Model.](#)

Solubility 8.71e+02 mg/ml ; 5.48e+00 mol/l

Class

Solubility class: Log S scale

[Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly](#) Highly soluble

Log S (Ali)

Ali: Topological method implemented from
[Ali J. et al. 2012 J. Chem. Inf. Model.](#)

0.74

Solubility 8.71e+02 mg/ml ; 5.47e+00 mol/l

Class

Solubility class: Log S scale

[Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly](#) Highly soluble

Log S (SILICOS-IT)

SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, <http://www.silicos-it.com>

-0.20

Solubility 1.02e+02 mg/ml ; 6.38e-01 mol/l

Class

Solubility class: Log S scale

[Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly](#) Soluble

Pharmacokinetics

GI absorption

Gastrointestinal absorption: according to the white of the BOILED-Egg Low

BBB permeant

BBB permeation: according to the yolk of the BOILED-Egg No

P-gp substrate No

P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set). 10-fold CV: ACC=0.72 / AUC=0.77

[Lipinski PA. et al. 2001
Adv. Drug. Deliv. Rev.](#)
Log $P_{o/w}$ (SILICOS-IT)



SILICOS-IT: Hybrid
fragmental/topological
method calculated by
FILTER-IT program, -1.27
version 1.0.2, courtesy
of SILICOS-IT,
[http://www.silicos-
it.com](http://www.silicos-
it.com)

Consensus Log $P_{o/w}$

Consensus Log $P_{o/w}$: -1.63
[Average of all five
predictions](#)

External: ACC=0.88 /
AUC=0.94

CYP1A2 inhibitor

**Cytochrome P450 1A2
inhibitor:** SVM model
built on 9145 molecules
(training set) No
and tested on 3000
molecules (test set)
10-fold CV: ACC=0.83 /
AUC=0.90
External: ACC=0.84 /
AUC=0.91

CYP2C19 inhibitor

**Cytochrome P450
2C19 inhibitor:** SVM
model built on 9272
molecules (training set) No
and tested on 3000
molecules (test set)
10-fold CV: ACC=0.80 /
AUC=0.86
External: ACC=0.80 /
AUC=0.87

CYP2C9 inhibitor

**Cytochrome P450 2C9
inhibitor:** SVM model
built on 5940 molecules
(training set) No
and tested on 2075
molecules (test set)
10-fold CV: ACC=0.78 /
AUC=0.85
External: ACC=0.71 /
AUC=0.81

CYP2D6 inhibitor

**Cytochrome P450 2D6
inhibitor:** SVM model
built on 3664 molecules
(training set) No
and tested on 1068
molecules (test set)
10-fold CV: ACC=0.79 /
AUC=0.85
External: ACC=0.81 /
AUC=0.87

CYP3A4 inhibitor

**Cytochrome P450 3A4
inhibitor:** SVM model
built on 7518 molecules
(training set) No
and tested on 2579
molecules (test set)
10-fold CV: ACC=0.77 /
AUC=0.85
External: ACC=0.78 /
AUC=0.86

Log K_p (skin
permeation)

Skin permeation: -8.81 cm/s
QSPR model
implemented from
Potts RO and Guy RH.
1992 Pharm. Res.

Druglikeness

Lipinski **Lipinski (Pfizer) filter:**

implemented from

[Lipinski CA. et al. 2001](#)[Adv. Drug Deliv. Rev.](#)

Yes; 0 violation

[MW < 500](#)[MLOGP < 4.15](#)[N or O < 10](#)[NH or OH < 5](#)Ghose **Ghose filter:**

implemented from

[Ghose AK. et al. 1999 J.](#)[Comb. Chem.](#)

No; 3 violations: MW<160,

WLOGP<-0.4, MR<40

[160 < MW < 480](#)[-0.4 < WLOGP < 5.6](#)[40 < MR < 130](#)[20 < atoms < 70](#)Veber **Veber (GSK) filter:**

implemented from

[Veber DE. et al. 2002 J.](#)[Med. Chem.](#)


Yes

[Rotatable bonds < 10](#)[TPSA < 140](#)Egan **Egan (Pharmacia)****filter:** implemented

from

[Egan WJ. et al. 2000 J.](#)[Med. Chem.](#)

Yes

[WLOGP < 5.88](#)[TPSA < 131.6](#)Muegge **Muegge (Bayer) filter:**

implemented from

[Muegge I. et al. 2001 J.](#)[Med. Chem.](#)[200 < MW < 600](#)[-2 < XLOGP < 5](#)

No; 2 violations: MW<200,

XLOGP3<-2

[TPSA < 150](#)[Num. rings < 7](#)[Num. carbon > 4](#)[Num. heteroatoms > 1](#)[Num. rotatable bonds <](#)[15](#)[H-bond acc. < 10](#)[H-bond don. < 5](#)Bioavailability Score **Abbott Bioavailability****Score: Probability of F**[> 10% in rat](#)

0.55

implemented from

[Martin YC. 2005 J.](#)[Med. Chem.](#)

Medicinal Chemistry

PAINS **Pan Assay Interference****Structures:**

implemented from

[Baell JB. & Holloway](#)[GA. 2010 J. Med.](#)[Chem.](#)

0 alert

Brenk

Structural Alert:

implemented from [Brenk R. et al. 2008 ChemMedChem](#) 0 alert

Leadlikeness



Leadlikeness:

implemented from [Teague S.J. 1999 Angew. Chem. Int. Ed.](#) No; 1 violation: MW<250
[250 < MW < 350](#)
[XLOGP < 3.5](#)
[Num. rotatable bonds < 7](#)

Synthetic accessibility

Synthetic accessibility:

score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penalties, trained on 12'782'590 molecules and tested on 40 external molecules ($r^2 = 0.94$) 2.99

Molecule 2

SMILES
S NCC(=O)N[C@H]1CONC1=O

Physicochemical Properties

Formula C5H9N3O3
 Molecular weight 159.14 g/mol
 Num. heavy atoms 11
 Num. arom. heavy atoms 0
 Fraction Csp3 0.60
 Num. rotatable bonds 3
 Num. H-bond acceptors 4
 Num. H-bond donors 3
 Molar Refractivity 37.75
 TPSA

Topological Polar

Surface Area: 93.45 Å²
 Calculated from [Ertl P. et al. 2000 J. Med. Chem.](#)

Lipophilicity

Log S (ESOL)

ESOL: Topological method implemented from [Delaney JS. 2004 J. Chem. Inf. Model.](#)

Solubility Class

Solubility class: Log S scale

[Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly](#) Highly soluble

Log S (Ali)

Ali: Topological method implemented from [Ali J. et al. 2012 J. Chem. Inf. Model.](#)

Solubility Class

Solubility class: Log S scale

[Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly](#) Highly soluble


Water Solubility

0.74

8.71e+02 mg/ml ; 5.48e+00 mol/l

8.71e+02 mg/ml ; 5.47e+00 mol/l

Log $P_{o/w}$ (iLOGP) [?]		Log S (SILICOS-IT) [?]	
iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	0.37	SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-0.20
Log $P_{o/w}$ (XLOGP3) [?]		Solubility Class [?]	1.02e+02 mg/ml ; 6.38e-01 mol/l
XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry.	-2.17	Solubility class: Log S scale Insoluble < -10 < Poorly Soluble < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	
Log $P_{o/w}$ (WLOGP) [?]		Pharmacokinetics	
WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	-2.89	GI absorption [?]	
Log $P_{o/w}$ (MLOGP) [?]		Gastrointestinal absorption: according to the white of the BOILED-Egg	Low
MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA, et al. 2001 Adv. Drug. Deliv. Rev.	-2.17	BBB permeant [?]	
Log $P_{o/w}$ (SILICOS-IT) [?]		BBB permeation: according to the yolk of the BOILED-Egg	No
SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-1.27	P-gp substrate [?]	
Consensus Log $P_{o/w}$ [?]		P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set). 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
Consensus Log $P_{o/w}$: Average of all five predictions	-1.63	CYP1A2 inhibitor [?]	
		Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set). 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	No
		CYP2C19 inhibitor [?]	
		Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set). 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No

CYP2C9 inhibitor **Cytochrome P450 2C9****inhibitor:** SVM model

built on 5940 molecules

(training set)


and tested on 2075 molecules (test set) No

10-fold CV: ACC=0.78 /

AUC=0.85

External: ACC=0.71 /

AUC=0.81

CYP2D6 inhibitor **Cytochrome P450 2D6****inhibitor:** SVM model

built on 3664 molecules

(training set)


and tested on 1068 molecules (test set) No

10-fold CV: ACC=0.79 /

AUC=0.85

External: ACC=0.81 /

AUC=0.87

CYP3A4 inhibitor **Cytochrome P450 3A4****inhibitor:** SVM model

built on 7518 molecules

(training set)


and tested on 2579 molecules (test set) No

10-fold CV: ACC=0.77 /

AUC=0.85

External: ACC=0.78 /

AUC=0.86

Log K_p (skin permeation) **Skin permeation:**

QSPR model


implemented from

Potts RO and Guy RH.

1992 Pharm. Res.

-8.81 cm/s

Druglikeness

Lipinski **Lipinski (Pfizer) filter:**

implemented from

Lipinski CA. et al. 2001

Adv. Drug Deliv. Rev.

MW < 500

MLOGP < 4.15

N or O < 10

NH or OH < 5

Yes; 0 violation

Ghose **Ghose filter:**

implemented from

Ghose AK. et al. 1999 J.

Comb. Chem.

160 < MW < 480

-0.4 < WLOGP < 5.6

40 < MR < 130

20 < atoms < 70

No; 3 violations: MW<160,
WLOGP<-0.4, MR<40Veber 

Yes

Veber (GSK) filter:

implemented from

Veber DE. et al. 2002 J.

Med. Chem.

[Rotatable bonds < 10](#)
[TPSA < 140](#)

Egan 

Egan (Pharmacia)

filter: [implemented](#)


[from](#)

[Egan W.J. et al. 2000 J.](#) Yes

[Med. Chem.](#)

[WLOGP < 5.88](#)

[TPSA < 131.6](#)

Muegge 

Muegge (Bayer) filter:

[implemented from](#)

[Muegge I. et al. 2001 J.](#)

[Med. Chem.](#)

[200 < MW < 600](#)

[-2 < XLOGP < 5](#)

No; 2 violations: MW<200,

XLOGP3<-2

[TPSA < 150](#)

[Num. rings < 7](#)

[Num. carbon > 4](#)

[Num. heteroatoms > 1](#)

[Num. rotatable bonds <](#)

[15](#)

[H-bond acc. < 10](#)

[H-bond don. < 5](#)

Bioavailability Score 

Abbott Bioavailability

Score: [Probability of F](#)

[> 10% in rat](#)

0.55

[implemented from](#)

[Martin Y.C. 2005 J.](#)

[Med. Chem.](#)

Medicinal Chemistry

PAINS 

Pan Assay Interference

Structures:

[implemented from](#)

0 alert

[Baell JB. & Holloway](#)

[GA. 2010 J. Med.](#)

[Chem.](#)

Brenk 

Structural Alert:

[implemented from](#)

0 alert

[Brenk R. et al. 2008](#)

[ChemMedChem](#)

Leadlikeness 

Leadlikeness:

[implemented from](#)

[Teague S.J. 1999 Angew.](#)

[Chem. Int. Ed.](#)


No; 1 violation: MW<250

[250 < MW < 350](#)

[XLOGP < 3.5](#)

[Num. rotatable bonds <](#)

[7](#)

Synthetic accessibility  2.99

Synthetic accessibility

score: [from 1 \(very](#)

[easy\) to 10 \(very](#)

[difficult\)](#)

[based on 1024](#)


[fragmental contributions](#)

[\(FP2\) modulated by size](#)

[and complexity penalties.](#)

trained on 12'782'590
molecules and tested on
40 external molecules
($r^2 = 0.94$)

Molecule 3



SMILES FC([C@@H])([C@H](C(=O)O)N)O)F
S

Physicochemical Properties

Formula C₄H₇F₂NO₃
Molecular weight 155.10 g/mol
Num. heavy atoms 10
Num. arom. heavy atoms 0
Fraction Csp³ 0.75
Num. rotatable bonds 3
Num. H-bond acceptors 6
Num. H-bond donors 3
Molar Refractivity 27.08
TPSA

Topological Polar Surface Area: 83.55 Å²
Calculated from Ertl P. et al. 2000 J. Med. Chem.

Lipophilicity

Log $P_{o/w}$ (iLOGP) -0.15
iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.

Log $P_{o/w}$ (XLOGP3) -2.45
XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry.

Log $P_{o/w}$ (WLOGP) -0.14
WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

Log S (ESOL)

ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.

Solubility Class 1.35e+03 mg/ml ; 8.71e+00 mol/l

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Log S (Ali)

Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.

Solubility Class 2.67e+03 mg/ml ; 1.72e+01 mol/l

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Log S (SILICOS-IT)

SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, <http://www.silicos-it.com>

Solubility Class 1.52e+03 mg/ml ; 9.79e+00 mol/l

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly


Water Solubility

0.94


Pharmacokinetics

GI absorption


Gastrointestinal absorption: according to the white of the BOILED-Egg High

Log $P_{o/w}$ (MLOGP) **MLOGP: Topological method implemented from**








[Moriguchi I. et al. 1992 Chem. Pharm. Bull.](#) -3.05
[Moriguchi I. et al. 1994 Chem. Pharm. Bull.](#)
[Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.](#)

Log $P_{o/w}$ (SILICOS-IT) **SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, <http://www.silicos-it.com>**


-0.64

Consensus Log $P_{o/w}$ **Consensus Log $P_{o/w}$: Average of all five predictions**

-1.29

BBB permeant **BBB permeation:** according to the yolk of the BOILED-Egg NoP-gp substrate **P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set). 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94** NoCYP1A2 inhibitor **Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set). 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91** NoCYP2C19 inhibitor **Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set). 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87** NoCYP2C9 inhibitor **Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set). 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81** NoCYP2D6 inhibitor **Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set). 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87** NoCYP3A4 inhibitor  No**Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set).**

and tested on 2579
 molecules (test set)
 10-fold CV: ACC=0.77 /
 AUC=0.85
 External: ACC=0.78 /
 AUC=0.86

Log K_p (skin
 permeation) 

Skin permeation:

[QSPR model](#) -8.99 cm/s
 implemented from
[Potts RO and Guy RH.](#)
[1992 Pharm. Res.](#)

Druglikeness

Lipinski 

Lipinski (Pfizer) filter:

implemented from
[Lipinski CA. et al. 2001](#)
[Adv. Drug Deliv. Rev.](#) Yes; 0 violation
 MW < 500
 MLOGP < 4.15
 N or O < 10
 NH or OH < 5

Ghose 

Ghose filter:

implemented from
[Ghose AK. et al. 1999 J.](#)
[Comb. Chem.](#) No; 3 violations: MW<160, MR<40,
 #atoms<20
 160 < MW < 480
 -0.4 < WLOGP < 5.6
 40 < MR < 130
 20 < atoms < 70

Veber 

Veber (GSK) filter:

implemented from
[Veber DF. et al. 2002 J.](#) Yes
[Med. Chem.](#)
 Rotatable bonds < 10
 TPSA < 140

Egan 


**Egan (Pharmacia)
 filter:** implemented

from
[Egan WJ. et al. 2000 J.](#) Yes
[Med. Chem.](#)
 WLOGP < 5.88
 TPSA < 131.6

Muegge 

Muegge (Bayer) filter:

implemented from
[Muegge I. et al. 2001 J.](#)
[Med. Chem.](#)
 200 < MW < 600
 -2 < XLOGP < 5
 TPSA < 150 No; 3 violations: MW<200,
 XLOGP3<-2, #C<5
 Num. rings < 7
 Num. carbon > 4
 Num. heteroatoms > 1
 Num. rotatable bonds <
 15
 H-bond acc. < 10
 H-bond don. < 5

Bioavailability Score **Abbott Bioavailability:****Score:** Probability of F

> 10% in rat 0.55

implemented from

[Martin YC. 2005 J.](#)[Med. Chem.](#)

Medicinal Chemistry

PAINS **Pan Assay Interference****Structures:**

implemented from 0 alert

[Baell JB. & Holloway](#)[GA. 2010 J. Med.](#)[Chem.](#)Brenk **Structural Alert:**


implemented from 0 alert

[Brenk R. et al. 2008](#)[ChemMedChem](#)Leadlikeness **Leadlikeness:**

implemented from

[Teague SJ. 1999 Angew.](#)[Chem. Int. Ed.](#)

No; 1 violation: MW<250

[250 < MW < 350](#)[XLOGP < 3.5](#)[Num. rotatable bonds <](#)[7](#)Synthetic accessibility **Synthetic accessibility****score:** from 1 (very

easy) to 10 (very

difficult)

based on 1024

fragmental contributions 2.12



(FP2) modulated by size

and complexity penalties.

trained on 12'782'590

molecules and tested on

40 external molecules

(r² = 0.94)Molecule 4 Log S (ESOL) **ESOL:** Topological method implemented from[Delaney JS. 2004 J.](#)[Chem. Inf. Model.](#)

Water Solubility

0.94

Solubility

1.35e+03 mg/ml ; 8.71e+00 mol/l

Class **Solubility class:** Log S scale

Insoluble < -10 < Poorly

< -6 < Moderately < -4

< Soluble < -2 Very < 0

< Highly

SMILES FC([C@H])([C@@H](C(=O)O)N)O)F

Physicochemical Properties


Formula C4H7F2NO3

Molecular weight 155.10 g/mol


Num. heavy atoms 10

Num. arom. heavy atoms	0	Log <i>S</i> (Ali)	
Fraction Csp3	0.75	Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	1.24
Num. rotatable bonds	3		
Num. H-bond acceptors	6		
Num. H-bond donors	3		
Molar Refractivity	27.08	Solubility	2.67e+03 mg/ml ; 1.72e+01 mol/l
TPSA		Class	
Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	83.55 Å ²	Solubility class: Log <i>S</i> scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Highly soluble
	Lipophilicity		
Log <i>P</i> _{o/w} (iLOGP)		Log <i>S</i> (SILICOS-IT)	
iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	0.30	SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	0.99
Log <i>P</i> _{o/w} (XLOGP3)		Solubility	1.52e+03 mg/ml ; 9.79e+00 mol/l
XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry.	-2.45	Class	
Log <i>P</i> _{o/w} (WLOGP)		Solubility class: Log <i>S</i> scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	-0.14		
Log <i>P</i> _{o/w} (MLOGP)			Pharmacokinetics
MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	-3.05	GI absorption	
Log <i>P</i> _{o/w} (SILICOS-IT)		Gastrointestinal absorption: according to the white of the BOILED-Egg	High
SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-0.64	BBB permeant	
Consensus Log <i>P</i> _{o/w}		BBB permeation: according to the yolk of the BOILED-Egg	No
Consensus Log <i>P</i>_{o/w}: Average of all five predictions	-1.20	P-gp substrate	
		P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set). 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
		CYP1A2 inhibitor	No
		Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set). 10-fold CV: ACC=0.83 / AUC=0.90	


[External: ACC=0.84 / AUC=0.91](#)

CYP2C19 inhibitor 


Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) No
 10-fold CV: ACC=0.80 / AUC=0.86
 External: ACC=0.80 / AUC=0.87

CYP2C9 inhibitor 


Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) No
 10-fold CV: ACC=0.78 / AUC=0.85
 External: ACC=0.71 / AUC=0.81

CYP2D6 inhibitor 

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) No
 10-fold CV: ACC=0.79 / AUC=0.85
 External: ACC=0.81 / AUC=0.87

CYP3A4 inhibitor 

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) No
 10-fold CV: ACC=0.77 / AUC=0.85
 External: ACC=0.78 / AUC=0.86

Log K_p (skin permeation) 

Skin permeation: QSPR model -8.99 cm/s
 implemented from Potts RO and Guy RH. 1992 Pharm. Res.

Druglikeness

Lipinski 

Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. Yes; 0 violation
 MW < 500
 MLOGP < 4.15
 N or O < 10
 NH or OH < 5

Ghose ?

Ghose filter:

implemented from

[Ghose AK. et al. 1999 J.](#)[Comb. Chem.](#)[160 < MW < 480](#)[-0.4 < WLOGP < 5.6](#)[40 < MR < 130](#)[20 < atoms < 70](#)No; 3 violations: MW<160, MR<40,
#atoms<20

Veber ?

Veber (GSK) filter:

implemented from

[Veber DF. et al. 2002 J.](#)[Med. Chem.](#)[Rotatable bonds < 10](#)[TPSA < 140](#)

Yes

Egan ?

Egan (Pharmacia)**filter:** implemented

from

[Egan WJ. et al. 2000 J.](#)[Med. Chem.](#)[WLOGP < 5.88](#)[TPSA < 131.6](#)

Yes

Muegge ?

Muegge (Bayer) filter:

implemented from

[Muegge I. et al. 2001 J.](#)[Med. Chem.](#)[200 < MW < 600](#)[-2 < XLOGP < 5](#)[TPSA < 150](#)[Num. rings < 7](#)[Num. carbon > 4](#)[Num. heteroatoms > 1](#)[Num. rotatable bonds <](#)[15](#)[H-bond acc. < 10](#)[H-bond don. < 5](#)No; 3 violations: MW<200,
XLOGP3<-2, #C<5

Bioavailability Score ?

Abbott Bioavailability**Score:** Probability of F[> 10% in rat](#)

implemented from

[Martin YC. 2005 J.](#)[Med. Chem.](#)

0.55

Medicinal Chemistry

PAINS ?

Pan Assay Interference**Structures:**

implemented from

[Baell JB. & Holloway.](#)[GA. 2010 J. Med.](#)[Chem.](#)

0 alert

Brenk ?

Structural Alert:

implemented from

[Brenk R. et al. 2008](#)[ChemMedChem](#)

0 alert

Leadlikeness ?

No; 1 violation: MW<250

Leadlikeness:

implemented from



Teague SJ. 1999 Angew.
Chem. Int. Ed.
250 < MW < 350
XLOGP < 3.5
Num. rotatable bonds <
7

Synthetic accessibility [?]

Synthetic accessibility

score: from 1 (very
easy) to 10 (very
difficult)
based on 1024
fragmental contributions 2.12
(FP2) modulated by size
and complexity penalties,
trained on 12'782'590
molecules and tested on
40 external molecules
($r^2 = 0.94$)

Molecule 5



SMILES
S FC([C@@H])([C@@H](C(=O)O)N)O

Physicochemical Properties

Formula	C4H7F2NO3
Molecular weight	155.10 g/mol
Num. heavy atoms	10
Num. arom. heavy atoms	0
Fraction Csp3	0.75
Num. rotatable bonds	3
Num. H-bond acceptors	6
Num. H-bond donors	3
Molar Refractivity	27.08
TPSA [?]	

Topological Polar

Surface Area:
Calculated from
Ertl P. et al. 2000 J.
Med. Chem.

83.55 Å²

Lipophilicity

Log $P_{o/w}$ (iLOGP) [?]

iLOGP: in-house
physics-based method
implemented from
Daina A et al. 2014 J.
Chem. Inf. Model.

0.34

Log $P_{o/w}$ (XLOGP3) [?] -2.45

XLOGP3: Atomistic
and knowledge-based

Log S (ESOL) [?]

ESOL: Topological
method implemented
from
Delaney JS. 2004 J.
Chem. Inf. Model.

Water Solubility

0.94

Solubility
Class [?]

1.35e+03 mg/ml ; 8.71e+00 mol/l

Solubility class: Log S
scale

Insoluble < -10 < Poorly
< -6 < Moderately < -4
< Soluble < -2 Very < 0
< Highly

Highly soluble

Log S (Ali) [?]

Ali: Topological method
implemented from
Ali J. et al. 2012 J.
Chem. Inf. Model.

1.24

Solubility
Class [?]

2.67e+03 mg/ml ; 1.72e+01 mol/l

Solubility class: Log S
scale

Insoluble < -10 < Poorly
< -6 < Moderately < -4
< Soluble < -2 Very < 0
< Highly

Highly soluble

Log S (SILICOS-IT) [?]

SILICOS-IT:
Fragmental method
calculated by
FILTER-IT program,
version 1.0.2, courtesy
of SILICOS-IT,
[http://www.silicos-
it.com](http://www.silicos-it.com)

0.99

Solubility

1.52e+03 mg/ml ; 9.79e+00 mol/l

[method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry.](#)

Log $P_{o/w}$ (WLOGP) [?]

WLOGP: Atomistic method implemented from

[Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.](#)

-0.14

Log $P_{o/w}$ (MLOGP) [?]

MLOGP: Topological method implemented from

[Moriguchi I. et al. 1992 Chem. Pharm. Bull.](#)

[Moriguchi I. et al. 1994 Chem. Pharm. Bull.](#)

[Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.](#)

-3.05

Log $P_{o/w}$ (SILICOS-IT) [?]

SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, <http://www.silicos-it.com>

-0.64

Consensus Log $P_{o/w}$ [?]

Consensus Log $P_{o/w}$: Average of all five predictions

-1.19

Class [?]

Solubility class: Log S scale

[Insoluble < -10 < Poorly Soluble < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly](#)

Pharmacokinetics

GI absorption [?]

Gastrointestinal absorption: according to the white of the BOILED-Egg High

BBB permeant [?]

BBB permeation: according to the yolk of the BOILED-Egg No

P-gp substrate [?]

P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set). No
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

CYP1A2 inhibitor [?]


Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set). No
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

CYP2C19 inhibitor [?]

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set). No
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

CYP2C9 inhibitor [?]

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set). No
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

CYP2D6 inhibitor **Cytochrome P450 2D6****inhibitor:** [SVM model](#)[built on 3664 molecules](#)[\(training set\)](#)

and tested on 1068 No


[molecules \(test set\)](#)

10-fold CV: ACC=0.79 /

AUC=0.85

External: ACC=0.81 /

AUC=0.87

CYP3A4 inhibitor **Cytochrome P450 3A4****inhibitor:** [SVM model](#)[built on 7518 molecules](#)[\(training set\)](#)

and tested on 2579 No


[molecules \(test set\)](#)

10-fold CV: ACC=0.77 /

AUC=0.85

External: ACC=0.78 /

AUC=0.86


Log K_p (skin permeation) **Skin permeation:**[QSPR model](#)

-8.99 cm/s

implemented from

[Potts RO and Guy RH.](#)[1992 Pharm. Res.](#)

Druglikeness

Lipinski **Lipinski (Pfizer) filter:**

implemented from

[Lipinski CA. et al. 2001](#)[Adv. Drug Deliv. Rev.](#)

Yes; 0 violation

[MW < 500](#)[MLOGP < 4.15](#)[N or O < 10](#)[NH or OH < 5](#)Ghose **Ghose filter:**

implemented from

[Ghose AK. et al. 1999 J.](#)[Comb. Chem.](#)No; 3 violations: MW<160, MR<40,
#atoms<20[160 < MW < 480](#)[-0.4 < WLOGP < 5.6](#)[40 < MR < 130](#)[20 < atoms < 70](#)Veber **Veber (GSK) filter:**

implemented from

[Veber DF. et al. 2002 J.](#)[Med. Chem.](#)

Yes


[Rotatable bonds < 10](#)[TPSA < 140](#)Egan **Egan (Pharmacia)****filter:** implemented

from


[Egan WJ. et al. 2000 J.](#)[Med. Chem.](#)

Yes

[WLOGP < 5.88](#)[TPSA < 131.6](#)

Muegge **Muegge (Bayer) filter:**

implemented from

[Muegge I. et al. 2001 J.](#)[Med. Chem.](#)[200 < MW < 600](#)[-2 < XLOGP < 5](#)[TPSA < 150](#)[Num. rings < 7](#)[Num. carbon > 4](#)[Num. heteroatoms > 1](#)[Num. rotatable bonds <](#)[15](#)[H-bond acc. < 10](#)[H-bond don. < 5](#)No; 3 violations: MW<200,
XLOGP3<-2, #C<5Bioavailability Score **Abbott Bioavailability****Score: Probability of F**[> 10% in rat](#)

0.55

implemented from

[Martin YC. 2005 J.](#)[Med. Chem.](#)

Medicinal Chemistry

PAINS **Pan Assay Interference****Structures:**

implemented from

0 alert

[Baell JB. & Holloway](#)[GA. 2010 J. Med.](#)[Chem.](#)Brenk **Structural Alert:**

implemented from


0 alert

[Brenk R. et al. 2008](#)[ChemMedChem](#)Leadlikeness **Leadlikeness:**

implemented from

[Teague SJ. 1999 Angew.](#)[Chem. Int. Ed.](#)

No; 1 violation: MW<250

[250 < MW < 350](#)[XLOGP < 3.5](#)[Num. rotatable bonds <](#)[7](#)Synthetic accessibility **Synthetic accessibility****score: from 1 (very****easy) to 10 (very****difficult)**

based on 1024



[fragmental contributions](#) 2.12[\(FP2\) modulated by size](#)[and complexity penalties,](#)[trained on 12'782'590](#)[molecules and tested on](#)[40 external molecules](#)[\(r² = 0.94\)](#)

Molecule 6



Water Solubility





SMILES N[C@H](C(=O)O)[C@@H](c1cnco1)O

Physicochemical Properties

Formula	C6H8N2O4
Molecular weight	172.14 g/mol
Num. heavy atoms	12
Num. arom. heavy atoms	5
Fraction Csp3	0.33
Num. rotatable bonds	3
Num. H-bond acceptors	6
Num. H-bond donors	3
Molar Refractivity	36.72
TPSA	

Topological Polar Surface Area: 109.58 Å²
 Calculated from Ertl P. et al. 2000 J. Med. Chem.

Lipophilicity
 Log $P_{o/w}$ (iLOGP)

iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model. 0.37

Log $P_{o/w}$ (XLOGP3)
XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry. -4.07

Log $P_{o/w}$ (WLOGP)
WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model. -1.20

Log $P_{o/w}$ (MLOGP)
MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. -4.55

Log S (ESOL)

ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model. 1.55

Solubility Class 6.06e+03 mg/ml ; 3.52e+01 mol/l

Solubility class: Log S scale
 Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Log S (Ali)

Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model. 2.37

Solubility Class 4.05e+04 mg/ml ; 2.35e+02 mol/l

Solubility class: Log S scale
 Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Log S (SILICOS-IT)

SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, <http://www.silicos-it.com> 0.23

Solubility Class 2.92e+02 mg/ml ; 1.69e+00 mol/l

Solubility class: Log S scale
 Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Pharmacokinetics

GI absorption

Gastrointestinal absorption: according to the white of the BOILED-Egg High

BBB permeant

BBB permeation: according to the yolk of the BOILED-Egg No

P-gp substrate No

P-glycoprotein substrate: SVM model built on 1033 molecules

[Lipinski PA. et al. 2001
Adv. Drug. Deliv. Rev.](#)

Log $P_{o/w}$ (SILICOS-IT)

SILICOS-IT: Hybrid
fragmental/topological
method calculated by
FILTER-IT program, -0.93
version 1.0.2, courtesy
of SILICOS-IT,
[http://www.silicos-
it.com](http://www.silicos-
it.com)

Consensus Log $P_{o/w}$

Consensus Log $P_{o/w}$: -2.08
[Average of all five
predictions](#)

(training set)
and tested on 415
molecules (test set)
10-fold CV: ACC=0.72 /
AUC=0.77
External: ACC=0.88 /
AUC=0.94
CYP1A2 inhibitor

**Cytochrome P450 1A2
inhibitor:** SVM model
built on 9145 molecules
(training set)
and tested on 3000 No
molecules (test set)
10-fold CV: ACC=0.83 /
AUC=0.90
External: ACC=0.84 /
AUC=0.91

CYP2C19 inhibitor

**Cytochrome P450
2C19 inhibitor:** SVM
model built on 9272
molecules (training set)
and tested on 3000 No
molecules (test set)
10-fold CV: ACC=0.80 /
AUC=0.86
External: ACC=0.80 /
AUC=0.87

CYP2C9 inhibitor

**Cytochrome P450 2C9
inhibitor:** SVM model
built on 5940 molecules
(training set)
and tested on 2075 No
molecules (test set)
10-fold CV: ACC=0.78 /
AUC=0.85
External: ACC=0.71 /
AUC=0.81

CYP2D6 inhibitor

**Cytochrome P450 2D6
inhibitor:** SVM model
built on 3664 molecules
(training set)
and tested on 1068 No
molecules (test set)
10-fold CV: ACC=0.79 /
AUC=0.85
External: ACC=0.81 /
AUC=0.87

CYP3A4 inhibitor

**Cytochrome P450 3A4
inhibitor:** SVM model
built on 7518 molecules
(training set)
and tested on 2579 No
molecules (test set)
10-fold CV: ACC=0.77 /
AUC=0.85
External: ACC=0.78 /
AUC=0.86

Log K_p (skin
permeation) -10.24 cm/s

Skin permeation:
QSPR model

[implemented from Potts RO and Guy RH. 1992 Pharm. Res.](#)

Druglikeness

Lipinski ?

Lipinski (Pfizer) filter:[implemented from](#)[Lipinski CA. et al. 2001](#)[Adv. Drug Deliv. Rev.](#)

Yes; 0 violation

[MW < 500](#)[MLOGP < 4.15](#)[N or O < 10](#)[NH or OH < 5](#)

Ghose ?

Ghose filter:[implemented from](#)[Ghose AK. et al. 1999 J.](#)[Comb. Chem.](#)

No; 2 violations: WLOGP < -0.4,

MR < 40

[160 < MW < 480](#)[-0.4 < WLOGP < 5.6](#)[40 < MR < 130](#)[20 < atoms < 70](#)

Veber ?

Veber (GSK) filter:[implemented from](#)[Veber DF. et al. 2002 J.](#)[Med. Chem.](#)

Yes

[Rotatable bonds < 10](#)[TPSA < 140](#)

Egan ?

Egan (Pharmacia)**filter:** [implemented](#)[from](#)[Egan WJ. et al. 2000 J.](#)[Med. Chem.](#)

Yes

[WLOGP < 5.88](#)[TPSA < 131.6](#)

Muegge ?

Muegge (Bayer) filter:[implemented from](#)[Muegge I. et al. 2001 J.](#)[Med. Chem.](#)[200 < MW < 600](#)[-2 < XLOGP < 5](#)

No; 2 violations: MW < 200,

XLOGP3 < -2

[TPSA < 150](#)[Num. rings < 7](#)[Num. carbon > 4](#)[Num. heteroatoms > 1](#)[Num. rotatable bonds < 15](#)[H-bond acc. < 10](#)[H-bond don. < 5](#)

Bioavailability Score ?

Abbott Bioavailability**Score: Probability of F**[> 10% in rat](#)

0.55

[implemented from](#)[Martin YC. 2005 J.](#)[Med. Chem.](#)

Medicinal Chemistry

PAINS ?

0 alert

Pan Assay Interference Structures:

[implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.](#)

Brenk

Structural Alert:

[implemented from Brenk R. et al. 2008 ChemMedChem](#) 0 alert

Leadlikeness

Leadlikeness:



[implemented from Teague SJ. 1999 Angew. Chem. Int. Ed.](#) No; 1 violation: MW<250
[250 < MW < 350](#)
[XLOGP < 3.5](#)
[Num. rotatable bonds < 7](#)

Synthetic accessibility

Synthetic accessibility

score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penalties, trained on 12'782'590 molecules and tested on 40 external molecules ($r^2 = 0.94$) 3.13

Molecule 7



SMILES FC([C@H])([C@H](C(=O)O)N)O

Physicochemical Properties

Formula C4H7F2NO3
 Molecular weight 155.10 g/mol
 Num. heavy atoms 10
 Num. arom. heavy atoms 0
 Fraction Csp3 0.75
 Num. rotatable bonds 3
 Num. H-bond acceptors 6
 Num. H-bond donors 3
 Molar Refractivity 27.08
 TPSA 83.55 Å²

Topological Polar

Surface Area:
[Calculated from](#)

Log S (ESOL)

ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model. 0.94

Solubility Class 1.35e+03 mg/ml ; 8.71e+00 mol/l

Solubility class: Log S scale
 Insoluble < -10 < Poorly soluble < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Log S (Ali)

Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model. 1.24

Solubility Class 2.67e+03 mg/ml ; 1.72e+01 mol/l Highly soluble

Solubility class: Log S scale
 Insoluble < -10 < Poorly soluble < -6 < Moderately < -4

[Ertl P. et al. 2000 J. Med. Chem.](#)

Lipophilicity

< Soluble < -2 Very < 0
< Highly

Log $P_{o/w}$ (iLOGP)

Log S (SILICOS-IT)

iLOGP: in-house physics-based method implemented from [Daina A et al. 2014 J. Chem. Inf. Model.](#)

0.11

SILICOS-IT: Fragmental method calculated by [FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, <http://www.silicos-it.com>](#)

0.99

Log $P_{o/w}$ (XLOGP3)

XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry.

-2.45

Solubility 1.52e+03 mg/ml ; 9.79e+00 mol/l
Class

Solubility class: Log S scale
Insoluble < -10 < Poorly Soluble
< -6 < Moderately < -4
< Soluble < -2 Very < 0
< Highly

Log $P_{o/w}$ (WLOGP)

WLOGP: Atomistic method implemented from [Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.](#)

-0.14

GI absorption

Pharmacokinetics

Gastrointestinal absorption: according to the white of the BOILED-Egg High

Log $P_{o/w}$ (MLOGP)

MLOGP: Topological method implemented from [Moriguchi I. et al. 1992 Chem. Pharm. Bull.](#) [Moriguchi I. et al. 1994 Chem. Pharm. Bull.](#) [Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.](#)

-3.05

BBB permeant

BBB permeation: according to the yolk of the BOILED-Egg No

P-gp substrate

P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set).
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94 No

Log $P_{o/w}$ (SILICOS-IT)

SILICOS-IT: Hybrid fragmental/topological method calculated by [FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, <http://www.silicos-it.com>](#)

-0.64

CYP1A2 inhibitor

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set).
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91 No

Consensus Log $P_{o/w}$

Consensus Log $P_{o/w}$: Average of all five predictions

-1.23

CYP2C19 inhibitor

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set).
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87 No

CYP2C9 inhibitor ⓘ

Cytochrome P450 2C9**inhibitor:** SVM model

built on 5940 molecules

(training set)

and tested on 2075 No

molecules (test set)

10-fold CV: ACC=0.78 /

AUC=0.85

External: ACC=0.71 /

AUC=0.81

CYP2D6 inhibitor ⓘ

Cytochrome P450 2D6**inhibitor:** SVM model

built on 3664 molecules

(training set)

and tested on 1068 No

molecules (test set)

10-fold CV: ACC=0.79 /

AUC=0.85

External: ACC=0.81 /

AUC=0.87

CYP3A4 inhibitor ⓘ

Cytochrome P450 3A4**inhibitor:** SVM model

built on 7518 molecules

(training set)

and tested on 2579 No

molecules (test set)

10-fold CV: ACC=0.77 /

AUC=0.85

External: ACC=0.78 /

AUC=0.86

Log K_p (skin
permeation) ⓘ**Skin permeation:**

QSPR model

-8.99 cm/s

implemented from

Potts RO and Guy RH.

1992 Pharm. Res.

Druglikeness

Lipinski ⓘ

Lipinski (Pfizer) filter:

implemented from

Lipinski CA. et al. 2001

Adv. Drug Deliv. Rev. Yes; 0 violation

MW < 500

MLOGP < 4.15

N or O < 10

NH or OH < 5

Ghose ⓘ

Ghose filter:

implemented from

Ghose AK. et al. 1999 J.

Comb. Chem.

No; 3 violations: MW<160, MR<40,
#atoms<20

160 < MW < 480

-0.4 < WLOGP < 5.6

40 < MR < 130

20 < atoms < 70

Veber ⓘ

Yes

Veber (GSK) filter:

implemented from

Veber DE. et al. 2002 J.

Med. Chem.

[Rotatable bonds < 10](#)
[TPSA < 140](#)

Egan

Egan (Pharmacia)

filter: [implemented](#)

[from](#)

[Egan W.J. et al. 2000 J.](#) Yes

[Med. Chem.](#)

[WLOGP < 5.88](#)

[TPSA < 131.6](#)

Muegge

Muegge (Bayer) filter:

[implemented from](#)

[Muegge I. et al. 2001 J.](#)

[Med. Chem.](#)

[200 < MW < 600](#)

[-2 < XLOGP < 5](#)

[TPSA < 150](#)

[Num. rings < 7](#)

[Num. carbon > 4](#)

[Num. heteroatoms > 1](#)

[Num. rotatable bonds <](#)

[15](#)

[H-bond acc. < 10](#)

[H-bond don. < 5](#)

No; 3 violations: MW<200,
XLOGP3<-2, #C<5

Bioavailability Score

Abbott Bioavailability

Score: [Probability of F](#)

[> 10% in rat](#)

0.55

[implemented from](#)

[Martin Y.C. 2005 J.](#)

[Med. Chem.](#)

Medicinal Chemistry

PAINS

Pan Assay Interference

Structures:

[implemented from](#)

0 alert

[Baell JB. & Holloway](#)

[GA. 2010 J. Med.](#)

[Chem.](#)

Brenk

Structural Alert:

[implemented from](#)

0 alert

[Brenk R. et al. 2008](#)

[ChemMedChem](#)

Leadlikeness

Leadlikeness:

[implemented from](#)

[Teague S.J. 1999 Angew.](#)

[Chem. Int. Ed.](#)

No; 1 violation: MW<250

[250 < MW < 350](#)

[XLOGP < 3.5](#)

[Num. rotatable bonds <](#)

[7](#)

Synthetic accessibility 2.12

Synthetic accessibility

score: [from 1 \(very](#)

[easy\) to 10 \(very](#)

[difficult\)](#)

[based on 1024](#)



[fragmental contributions](#)

[\(FP2\) modulated by size](#)

[and complexity penalties.](#)

trained on 12'782'590
molecules and tested on
40 external molecules
($r^2 = 0.94$)

Molecule 8



SMILES N[C@@H](C(=O)O)[C@H](c1cnco1)O

Physicochemical Properties

Formula	C6H8N2O4
Molecular weight	172.14 g/mol
Num. heavy atoms	12
Num. arom. heavy atoms	5
Fraction Csp3	0.33
Num. rotatable bonds	3
Num. H-bond acceptors	6
Num. H-bond donors	3
Molar Refractivity	36.72
TPSA	

Topological Polar Surface Area:
Calculated from
Ertl P. et al. 2000 J.
Med. Chem.

109.58 Å²

Lipophilicity

Log $P_{o/w}$ (iLOGP)

iLOGP: in-house
physics-based method
implemented from
Daina A et al. 2014 J.
Chem. Inf. Model.

0.29

Log $P_{o/w}$ (XLOGP3)

XLOGP3: Atomistic
and knowledge-based
method calculated by
XLOGP program,
version 3.2.2, courtesy
of CCBG, Shanghai
Institute of Organic
Chemistry.

-4.07

Log $P_{o/w}$ (WLOGP)

WLOGP: Atomistic
method implemented
from
Wildman SA and
Crippen GM. 1999 J.
Chem. Inf. Model.

-1.20

Log S (ESOL)

ESOL: Topological
method implemented
from
Delaney JS. 2004 J.
Chem. Inf. Model.

Water Solubility

1.55

Solubility
Class

6.06e+03 mg/ml ; 3.52e+01 mol/l

Solubility class: Log S
scale
Insoluble < -10 < Poorly
< -6 < Moderately < -4
< Soluble < -2 Very < 0
< Highly

Highly soluble

Log S (Ali)

Ali: Topological method
implemented from
Ali J. et al. 2012 J.
Chem. Inf. Model.

2.37

Solubility
Class

4.05e+04 mg/ml ; 2.35e+02 mol/l

Solubility class: Log S
scale
Insoluble < -10 < Poorly
< -6 < Moderately < -4
< Soluble < -2 Very < 0
< Highly

Highly soluble

Log S (SILICOS-IT)

SILICOS-IT:
Fragmental method
calculated by
FILTER-IT program,
version 1.0.2, courtesy
of SILICOS-IT,
[http://www.silicos-
it.com](http://www.silicos-it.com)

0.23

Solubility
Class

2.92e+02 mg/ml ; 1.69e+00 mol/l

Solubility class: Log S
scale
Insoluble < -10 < Poorly
< -6 < Moderately < -4
< Soluble < -2 Very < 0
< Highly


Soluble

Pharmacokinetics


GI absorption

**Gastrointestinal
absorption:** according
to the white of the
BOILED-Egg

High


Log $P_{o/w}$ (MLOGP) **MLOGP: Topological method implemented from**

[Moriguchi I. et al. 1992 Chem. Pharm. Bull.](#) -4.55
[Moriguchi I. et al. 1994 Chem. Pharm. Bull.](#)
[Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.](#)

Log $P_{o/w}$ (SILICOS-IT) 


SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, <http://www.silicos-it.com>

-0.93


Consensus Log $P_{o/w}$ 

Consensus Log $P_{o/w}$: Average of all five predictions


-2.09

BBB permeant 


BBB permeation: according to the yolk of the BOILED-Egg No

P-gp substrate 


P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) No
 10-fold CV: ACC=0.72 / AUC=0.77
 External: ACC=0.88 / AUC=0.94

CYP1A2 inhibitor 


Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) No
 10-fold CV: ACC=0.83 / AUC=0.90
 External: ACC=0.84 / AUC=0.91

CYP2C19 inhibitor 


Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) No
 10-fold CV: ACC=0.80 / AUC=0.86
 External: ACC=0.80 / AUC=0.87

CYP2C9 inhibitor 

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) No
 10-fold CV: ACC=0.78 / AUC=0.85
 External: ACC=0.71 / AUC=0.81

CYP2D6 inhibitor 

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) No
 10-fold CV: ACC=0.79 / AUC=0.85
 External: ACC=0.81 / AUC=0.87

CYP3A4 inhibitor  No

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)

and tested on 2579
 molecules (test set)
 10-fold CV: ACC=0.77 /
 AUC=0.85
 External: ACC=0.78 /
 AUC=0.86

Log K_p (skin
 permeation) ?

Skin permeation:

[QSPR model](#) -10.24 cm/s
 implemented from
[Potts RO and Guy RH.](#)
[1992 Pharm. Res.](#)

Druglikeness

Lipinski ?

Lipinski (Pfizer) filter:

implemented from
[Lipinski CA. et al. 2001](#)
[Adv. Drug Deliv. Rev.](#) Yes; 0 violation
 MW < 500
 MLOGP < 4.15
 N or O < 10
 NH or OH < 5

Ghose ?

Ghose filter:

implemented from
[Ghose AK. et al. 1999 J.](#)
[Comb. Chem.](#) No; 2 violations: WLOGP<-0.4,
 MR<40
 160 < MW < 480
 -0.4 < WLOGP < 5.6
 40 < MR < 130
 20 < atoms < 70

Veber ?

Veber (GSK) filter:

implemented from
[Veber DF. et al. 2002 J.](#) Yes
[Med. Chem.](#)
 Rotatable bonds < 10
 TPSA < 140

Egan ?

**Egan (Pharmacia)
 filter:** implemented

from
[Egan WJ. et al. 2000 J.](#) Yes
[Med. Chem.](#)
 WLOGP < 5.88
 TPSA < 131.6

Muegge ?

Muegge (Bayer) filter:

implemented from
[Muegge I. et al. 2001 J.](#)
[Med. Chem.](#)
 200 < MW < 600
 -2 < XLOGP < 5
 TPSA < 150 No; 2 violations: MW<200,
 XLOGP3<-2
 Num. rings < 7
 Num. carbon > 4
 Num. heteroatoms > 1
 Num. rotatable bonds <
 15
 H-bond acc. < 10
 H-bond don. < 5

Bioavailability Score ?**Abbott Bioavailability:****Score:** Probability of F

> 10% in rat 0.55

implemented from

Martin YC. 2005 J.

Med. Chem.

Medicinal Chemistry

PAINS ?**Pan Assay Interference****Structures:**

implemented from 0 alert

Baell JB. & Holloway

GA. 2010 J. Med.

Chem.

Brenk ?**Structural Alert:**

implemented from 0 alert

Brenk R. et al. 2008

ChemMedChem

Leadlikeness ?**Leadlikeness:**

implemented from

Teague SJ. 1999 Angew.

Chem. Int. Ed.

No; 1 violation: MW<250

250 < MW < 350

XLOGP < 3.5

Num. rotatable bonds <

7

Synthetic accessibility ?**Synthetic accessibility****score:** from 1 (very

easy) to 10 (very

difficult)

based on 1024

fragmental contributions 3.13

(FP2) modulated by size

and complexity penalties.



trained on 12'782'590

molecules and tested on

40 external molecules

(r² = 0.94)

Molecule 9



Water Solubility

Log S (ESOL) ?**ESOL:** Topological

method implemented

from

Delaney JS. 2004 J.

Chem. Inf. Model.

1.97

Solubility

1.41e+04 mg/ml ; 9.39e+01 mol/l

Class ?**Solubility class:** Log S

scale

Insoluble < -10 < Poorly

< -6 < Moderately < -4

< Soluble < -2 Very < 0

< Highly

SMILES OC(=O)[C@H](F)[C@@H](N)C(=O)N

Physicochemical Properties


Formula C4H7FN2O3

Molecular weight 150.11 g/mol


Num. heavy atoms 10

Num. arom. heavy atoms	0	Log <i>S</i> (Ali)	
Fraction Csp3	0.50	Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	2.41
Num. rotatable bonds	3		
Num. H-bond acceptors	5		
Num. H-bond donors	3		
Molar Refractivity	28.78	Solubility Class	3.83e+04 mg/ml ; 2.55e+02 mol/l
TPSA		Solubility class: Log <i>S</i> scale	
Topological Polar Surface Area:	106.41 Å ²	Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Highly soluble
Calculated from Ertl P. et al. 2000 J. Med. Chem.			
	Lipophilicity		
Log <i>P</i> _{o/w} (iLOGP)		Log <i>S</i> (SILICOS-IT)	
iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	-0.26	SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	1.16
Log <i>P</i> _{o/w} (XLOGP3)		Solubility Class	2.15e+03 mg/ml ; 1.44e+01 mol/l
XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry.	-4.04	Solubility class: Log <i>S</i> scale	Soluble
Log <i>P</i> _{o/w} (WLOGP)		Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	
WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	-1.36		
Log <i>P</i> _{o/w} (MLOGP)			Pharmacokinetics
MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	-3.78	GI absorption	
		Gastrointestinal absorption: according to the white of the BOILED-Egg	High
Log <i>P</i> _{o/w} (SILICOS-IT)		BBB permeant	
SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-1.46	BBB permeation: according to the yolk of the BOILED-Egg	No
Consensus Log <i>P</i> _{o/w}		P-gp substrate	
Consensus Log <i>P</i>_{o/w}: Average of all five predictions	-2.18	P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set). 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
		CYP1A2 inhibitor	No
		Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set). 10-fold CV: ACC=0.83 / AUC=0.90	


[External: ACC=0.84 / AUC=0.91](#)

CYP2C19 inhibitor 


Cytochrome P450 2C19 inhibitor: SVM model built on [9272 molecules \(training set\)](#) and tested on [3000 molecules \(test set\)](#) No
 10-fold CV: ACC=0.80 / AUC=0.86
 External: ACC=0.80 / AUC=0.87

CYP2C9 inhibitor 


Cytochrome P450 2C9 inhibitor: SVM model built on [5940 molecules \(training set\)](#) and tested on [2075 molecules \(test set\)](#) No
 10-fold CV: ACC=0.78 / AUC=0.85
 External: ACC=0.71 / AUC=0.81

CYP2D6 inhibitor 

Cytochrome P450 2D6 inhibitor: SVM model built on [3664 molecules \(training set\)](#) and tested on [1068 molecules \(test set\)](#) No
 10-fold CV: ACC=0.79 / AUC=0.85
 External: ACC=0.81 / AUC=0.87

CYP3A4 inhibitor 

Cytochrome P450 3A4 inhibitor: SVM model built on [7518 molecules \(training set\)](#) and tested on [2579 molecules \(test set\)](#) No
 10-fold CV: ACC=0.77 / AUC=0.85
 External: ACC=0.78 / AUC=0.86

Log K_p (skin permeation) 

Skin permeation: QSPR model implemented from [Potts RO and Guy RH. 1992 Pharm. Res.](#) -10.08 cm/s

Druglikeness

Lipinski 

Lipinski (Pfizer) filter: implemented from [Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.](#) Yes; 0 violation
 MW < 500
 MLOGP < 4.15
 N or O < 10
 NH or OH < 5

Ghose **Ghose filter:**

implemented from

[Ghose AK. et al. 1999 J.](#)[Comb. Chem.](#)[160 < MW < 480](#)[-0.4 < WLOGP < 5.6](#)[40 < MR < 130](#)[20 < atoms < 70](#)No; 4 violations: MW<160,
WLOGP<-0.4, MR<40, #atoms<20Veber **Veber (GSK) filter:**

implemented from

[Veber DF. et al. 2002 J.](#)[Med. Chem.](#)[Rotatable bonds < 10](#)[TPSA < 140](#)


Yes

Egan **Egan (Pharmacia)****filter:** implemented


from

[Egan WJ. et al. 2000 J.](#)[Med. Chem.](#)[WLOGP < 5.88](#)[TPSA < 131.6](#)

Yes

Muegge **Muegge (Bayer) filter:**

implemented from

[Muegge I. et al. 2001 J.](#)[Med. Chem.](#)[200 < MW < 600](#)[-2 < XLOGP < 5](#)[TPSA < 150](#)[Num. rings < 7](#)[Num. carbon > 4](#)[Num. heteroatoms > 1](#)[Num. rotatable bonds <](#)[15](#)[H-bond acc. < 10](#)[H-bond don. < 5](#)No; 3 violations: MW<200,
XLOGP3<-2, #C<5Bioavailability Score **Abbott Bioavailability****Score:** Probability of F[> 10% in rat](#)

implemented from

[Martin YC. 2005 J.](#)[Med. Chem.](#)

0.55

Medicinal Chemistry

PAINS **Pan Assay Interference****Structures:**

implemented from

[Baell JB. & Holloway.](#)[GA. 2010 J. Med.](#)[Chem.](#)

0 alert

Brenk **Structural Alert:**

implemented from

[Brenk R. et al. 2008](#)[ChemMedChem](#)

0 alert

Leadlikeness 

No; 1 violation: MW<250

Leadlikeness:

implemented from



Teague SJ. 1999 Angew.
Chem. Int. Ed.
250 < MW < 350
XLOGP < 3.5
Num. rotatable bonds <
7

Synthetic accessibility [?]

Synthetic accessibility

score: from 1 (very
easy) to 10 (very
difficult)
based on 1024
fragmental contributions 2.18
(FP2) modulated by size
and complexity penalties,
trained on 12'782'590
molecules and tested on
40 external molecules
($r^2 = 0.94$)

Molecule 10



SMILES OC(=O)[C@H](F)[C@@H](N)C(=O)N

Physicochemical Properties

Formula C4H7FN2O3
Molecular weight 150.11 g/mol
Num. heavy atoms 10
Num. arom. heavy atoms 0
Fraction Csp3 0.50
Num. rotatable bonds 3
Num. H-bond acceptors 5
Num. H-bond donors 3
Molar Refractivity 28.78
TPSA [?]

Topological Polar Surface Area:
Calculated from
Ertl P. et al. 2000 J.
Med. Chem.

106.41 Å²

Lipophilicity

Log $P_{o/w}$ (iLOGP) [?]

iLOGP: in-house
physics-based method
implemented from
Daina A et al. 2014 J.
Chem. Inf. Model.

0.02

Log $P_{o/w}$ (XLOGP3) [?] -4.04

XLOGP3: Atomistic
and knowledge-based

Log S (ESOL) [?]

ESOL: Topological
method implemented
from
Delaney JS. 2004 J.
Chem. Inf. Model.

Water Solubility

1.97

Solubility
Class [?]

1.41e+04 mg/ml ; 9.39e+01 mol/l

**Solubility class: Log S
scale**
Insoluble < -10 < Poorly
< -6 < Moderately < -4
< Soluble < -2 Very < 0
< Highly

Highly soluble

Log S (Ali) [?]

Ali: Topological method
implemented from
Ali J. et al. 2012 J.
Chem. Inf. Model.

2.41

Solubility
Class [?]

3.83e+04 mg/ml ; 2.55e+02 mol/l

**Solubility class: Log S
scale**
Insoluble < -10 < Poorly
< -6 < Moderately < -4
< Soluble < -2 Very < 0
< Highly

Highly soluble

Log S (SILICOS-IT) [?]

SILICOS-IT:
Fragmental method
calculated by
FILTER-IT program,
version 1.0.2, courtesy
of SILICOS-IT,
[http://www.silicos-
it.com](http://www.silicos-it.com)

1.16

Solubility

2.15e+03 mg/ml ; 1.44e+01 mol/l

[method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry.](#)

Log $P_{o/w}$ (WLOGP) [?]

WLOGP: Atomistic method implemented from

[Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.](#)

-1.36

Log $P_{o/w}$ (MLOGP) [?]

MLOGP: Topological method implemented from

[Moriguchi I. et al. 1992 Chem. Pharm. Bull.](#)

[Moriguchi I. et al. 1994 Chem. Pharm. Bull.](#)

[Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.](#)

-3.78

Log $P_{o/w}$ (SILICOS-IT) [?]

SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, <http://www.silicos-it.com>

-1.46

Consensus Log $P_{o/w}$ [?]

Consensus Log $P_{o/w}$: Average of all five predictions

-2.12

Class [?]

Solubility class: Log S scale

[Insoluble < -10 < Poorly Soluble < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly](#)

Pharmacokinetics

GI absorption [?]

Gastrointestinal absorption: according to the white of the BOILED-Egg High

BBB permeant [?]

BBB permeation: according to the yolk of the BOILED-Egg No

P-gp substrate [?]

P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set). No
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

CYP1A2 inhibitor [?]

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set). No
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

CYP2C19 inhibitor [?]

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set). No
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

CYP2C9 inhibitor [?]

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set). No
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

CYP2D6 inhibitor ?

Cytochrome P450 2D6**inhibitor:** [SVM model](#)[built on 3664 molecules](#)[\(training set\)](#)

and tested on 1068 No

[molecules \(test set\)](#)

10-fold CV: ACC=0.79 /

AUC=0.85

External: ACC=0.81 /

AUC=0.87

CYP3A4 inhibitor ?

Cytochrome P450 3A4**inhibitor:** [SVM model](#)[built on 7518 molecules](#)[\(training set\)](#)

and tested on 2579 No

[molecules \(test set\)](#)

10-fold CV: ACC=0.77 /

AUC=0.85

External: ACC=0.78 /

AUC=0.86

Log K_p (skin permeation) ?**Skin permeation:**[QSPR model](#)

-10.08 cm/s

[implemented from](#)[Potts RO and Guy RH.](#)[1992 Pharm. Res.](#)

Druglikeness

Lipinski ?

Lipinski (Pfizer) filter:[implemented from](#)[Lipinski CA. et al. 2001](#)[Adv. Drug Deliv. Rev.](#)

Yes; 0 violation

[MW < 500](#)[MLOGP < 4.15](#)[N or O < 10](#)[NH or OH < 5](#)

Ghose ?

Ghose filter:[implemented from](#)[Ghose AK. et al. 1999 J.](#)[Comb. Chem.](#)No; 4 violations: MW<160,
WLOGP<-0.4, MR<40, #atoms<20[160 < MW < 480](#)[-0.4 < WLOGP < 5.6](#)[40 < MR < 130](#)[20 < atoms < 70](#)

Veber ?

Veber (GSK) filter:[implemented from](#)[Veber DF. et al. 2002 J.](#)[Med. Chem.](#)

Yes


[Rotatable bonds < 10](#)[TPSA < 140](#)

Egan ?


Egan (Pharmacia)**filter:** [implemented](#)[from](#)[Egan WJ. et al. 2000 J.](#)[Med. Chem.](#)

Yes

[WLOGP < 5.88](#)[TPSA < 131.6](#)

Muegge **Muegge (Bayer) filter:**

implemented from

[Muegge I. et al. 2001 J.](#)[Med. Chem.](#)[200 < MW < 600](#)[-2 < XLOGP < 5](#)[TPSA < 150](#)[Num. rings < 7](#)[Num. carbon > 4](#)[Num. heteroatoms > 1](#)[Num. rotatable bonds <](#)[15](#)[H-bond acc. < 10](#)[H-bond don. < 5](#)No; 3 violations: MW<200,
XLOGP3<-2, #C<5Bioavailability Score **Abbott Bioavailability****Score: Probability of F**[> 10% in rat](#)

0.55

implemented from

[Martin YC. 2005 J.](#)[Med. Chem.](#)

Medicinal Chemistry

PAINS **Pan Assay Interference****Structures:**

implemented from

0 alert

[Baell JB. & Holloway](#)[GA. 2010 J. Med.](#)[Chem.](#)Brenk **Structural Alert:**

implemented from


0 alert

[Brenk R. et al. 2008](#)[ChemMedChem](#)Leadlikeness **Leadlikeness:**

implemented from

[Teague SJ. 1999 Angew.](#)[Chem. Int. Ed.](#)

No; 1 violation: MW<250

[250 < MW < 350](#)[XLOGP < 3.5](#)[Num. rotatable bonds <](#)[7](#)Synthetic accessibility **Synthetic accessibility****score: from 1 (very****easy) to 10 (very****difficult)**

based on 1024



[fragmental contributions](#) 2.18[\(FP2\) modulated by size](#)[and complexity penalties,](#)[trained on 12'782'590](#)[molecules and tested on](#)[40 external molecules](#)[\(r² = 0.94\)](#)

Molecule 11



Water Solubility





SMILES ClC[C@H]([C@@H](C(=O)O)N)O

Physicochemical Properties

Formula	C4H8CINO3
Molecular weight	153.56 g/mol
Num. heavy atoms	9
Num. arom. heavy atoms	0
Fraction Csp3	0.75
Num. rotatable bonds	3
Num. H-bond acceptors	4
Num. H-bond donors	3
Molar Refractivity	31.78
TPSA	

Topological Polar Surface Area: 83.55 Å²
 Calculated from Ertl P. et al. 2000 J. Med. Chem.

Lipophilicity
 Log $P_{o/w}$ (iLOGP)

iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model. 0.80

Log $P_{o/w}$ (XLOGP3)
XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry. -2.72

Log $P_{o/w}$ (WLOGP)
WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model. -1.00

Log $P_{o/w}$ (MLOGP)
MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. -3.05

Log S (ESOL)

ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model. 1.12

Solubility Class 2.02e+03 mg/ml ; 1.32e+01 mol/l

Solubility class: Log S scale
 Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Log S (Ali)

Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model. 1.52

Solubility Class 5.05e+03 mg/ml ; 3.29e+01 mol/l

Solubility class: Log S scale
 Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Log S (SILICOS-IT)

SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, <http://www.silicos-it.com> 0.58

Solubility Class 5.81e+02 mg/ml ; 3.78e+00 mol/l

Solubility class: Log S scale
 Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Pharmacokinetics

GI absorption

Gastrointestinal absorption: according to the white of the BOILED-Egg High

BBB permeant

BBB permeation: according to the yolk of the BOILED-Egg No

P-gp substrate No

P-glycoprotein substrate: SVM model built on 1033 molecules

[Lipinski PA. et al. 2001
Adv. Drug. Deliv. Rev.](#)

Log $P_{o/w}$ (SILICOS-IT)

SILICOS-IT: Hybrid
fragmental/topological
method calculated by
FILTER-IT program, -0.70
version 1.0.2, courtesy
of SILICOS-IT,
[http://www.silicos-
it.com](http://www.silicos-
it.com)

Consensus Log $P_{o/w}$

Consensus Log $P_{o/w}$: -1.33
[Average of all five
predictions](#)

(training set)
and tested on 415
molecules (test set)
10-fold CV: ACC=0.72 /
AUC=0.77
External: ACC=0.88 /
AUC=0.94
CYP1A2 inhibitor

**Cytochrome P450 1A2
inhibitor:** SVM model
built on 9145 molecules
(training set)
and tested on 3000 No
molecules (test set)
10-fold CV: ACC=0.83 /
AUC=0.90
External: ACC=0.84 /
AUC=0.91

CYP2C19 inhibitor

**Cytochrome P450
2C19 inhibitor:** SVM
model built on 9272
molecules (training set)
and tested on 3000 No
molecules (test set)
10-fold CV: ACC=0.80 /
AUC=0.86
External: ACC=0.80 /
AUC=0.87

CYP2C9 inhibitor

**Cytochrome P450 2C9
inhibitor:** SVM model
built on 5940 molecules
(training set)
and tested on 2075 No
molecules (test set)
10-fold CV: ACC=0.78 /
AUC=0.85
External: ACC=0.71 /
AUC=0.81

CYP2D6 inhibitor

**Cytochrome P450 2D6
inhibitor:** SVM model
built on 3664 molecules
(training set)
and tested on 1068 No
molecules (test set)
10-fold CV: ACC=0.79 /
AUC=0.85
External: ACC=0.81 /
AUC=0.87

CYP3A4 inhibitor

**Cytochrome P450 3A4
inhibitor:** SVM model
built on 7518 molecules
(training set)
and tested on 2579 No
molecules (test set)
10-fold CV: ACC=0.77 /
AUC=0.85
External: ACC=0.78 /
AUC=0.86

Log K_p (skin
permeation) -9.17 cm/s

Skin permeation:
QSPR model

[implemented from
Potts RO and Guy RH.
1992 Pharm. Res.](#)

Druglikeness

Lipinski ?

Lipinski (Pfizer) filter:

[implemented from
Lipinski CA. et al. 2001
Adv. Drug Deliv. Rev.
MW < 500
MLOGP < 4.15
N or O < 10
NH or OH < 5](#)

Yes; 0 violation

Ghose ?

Ghose filter:

[implemented from
Ghose AK. et al. 1999 J.
Comb. Chem.
160 < MW < 480
-0.4 < WLOGP < 5.6
40 < MR < 130
20 < atoms < 70](#)

No; 4 violations: MW<160,
WLOGP<-0.4, MR<40, #atoms<20

Veber ?

Veber (GSK) filter:

[implemented from
Veber DF. et al. 2002 J.
Med. Chem.
Rotatable bonds < 10
TPSA < 140](#)

Yes

Egan ?

**Egan (Pharmacia)
filter:**

[implemented
from
Egan WJ. et al. 2000 J.
Med. Chem.
WLOGP < 5.88
TPSA < 131.6](#)

Yes

Muegge ?

Muegge (Bayer) filter:

[implemented from
Muegge I. et al. 2001 J.
Med. Chem.
200 < MW < 600
-2 < XLOGP < 5
TPSA < 150
Num. rings < 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds < 15
H-bond acc. < 10
H-bond don. < 5](#)

No; 3 violations: MW<200,
XLOGP3<-2, #C<5

Bioavailability Score ?

Abbott Bioavailability

Score: Probability of F
[> 10% in rat
implemented from
Martin YC. 2005 J.
Med. Chem.](#)

0.55

Medicinal Chemistry

PAINS ?

0 alert

**Pan Assay Interference
Structures:**


implemented from
Baell JB. & Holloway
GA. 2010 J. Med.
Chem.

Brenk

1 alert: alkyl_halide

Structural Alert:

implemented from
Brenk R. et al. 2008
ChemMedChem



alkyl_halide

Leadlikeness

Leadlikeness:

implemented from
Teague SJ. 1999 Angew.
Chem. Int. Ed.
 $250 < MW < 350$
 $XLOGP < 3.5$
Num. rotatable bonds < 7



No; 1 violation: MW<250

Synthetic accessibility

Synthetic accessibility.

score: from 1 (very
easy) to 10 (very
difficult)
based on 1024
fragmental contributions
(FP2) modulated by size
and complexity penalties,
trained on 12'782'590
molecules and tested on
40 external molecules
($r^2 = 0.94$)

2.52

Molecule 12Log *S* (ESOL)

Water Solubility

**ESOL: Topological
method implemented
from**
Delaney JS. 2004 J.
Chem. Inf. Model.

1.97

Solubility
Class

1.41e+04 mg/ml ; 9.39e+01 mol/l

**Solubility class: Log *S*
scale**
Insoluble $< -10 < Poorly$
 $< -6 < Moderately < -4$
 $< Soluble < -2 Very < 0$
 $< Highly$

Highly soluble

SMILES OC(=O)[C@H](F)[C@@H](N)C(=O)N

Physicochemical Properties

Formula C4H7FN2O3
Molecular weight 150.11 g/mol
Num. heavy atoms 10
Num. arom. heavy atoms 0
Fraction Csp3 0.50
Num. rotatable bonds 3
Num. H-bond acceptors 5
Num. H-bond donors 3
Molar Refractivity 28.78
TPSA 106.41 Å²

Log *S* (Ali)

**Ali: Topological method
implemented from**
Ali J. et al. 2012 J.
Chem. Inf. Model.

2.41

Solubility
Class 3.83e+04 mg/ml ; 2.55e+02 mol/l
Highly soluble

**Topological Polar
Surface Area:**
Calculated from

**Solubility class: Log *S*
scale**
Insoluble $< -10 < Poorly$
 $< -6 < Moderately < -4$

Ertl P. et al. 2000 J. Med. Chem.		< Soluble < -2 Very < 0 < Highly
Log $P_{o/w}$ (iLOGP)	Lipophilicity	Log S (SILICOS-IT)
iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	-0.19	SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT. http://www.silicos-it.com
Log $P_{o/w}$ (XLOGP3)		1.16
XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry.	-4.04	Solubility Class
Log $P_{o/w}$ (WLOGP)		2.15e+03 mg/ml ; 1.44e+01 mol/l
WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	-1.36	Solubility class: Log S scale Insoluble < -10 < Poorly Soluble < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly
Log $P_{o/w}$ (MLOGP)		Pharmacokinetics
MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	-3.78	GI absorption
Log $P_{o/w}$ (SILICOS-IT)		Gastrointestinal absorption: according to the white of the BOILED-Egg High
SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT. http://www.silicos-it.com	-1.46	BBB permeant
Consensus Log $P_{o/w}$		BBB permeation: according to the yolk of the BOILED-Egg No
Consensus Log $P_{o/w}$: Average of all five predictions	-2.17	P-gp substrate
		P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) No 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94
		CYP1A2 inhibitor
		Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) No 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91
		CYP2C19 inhibitor
		Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) No 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87

CYP2C9 inhibitor ⓘ

Cytochrome P450 2C9**inhibitor:** SVM model

built on 5940 molecules

(training set)

and tested on 2075 No

molecules (test set)

10-fold CV: ACC=0.78 /

AUC=0.85

External: ACC=0.71 /

AUC=0.81

CYP2D6 inhibitor ⓘ

Cytochrome P450 2D6**inhibitor:** SVM model

built on 3664 molecules

(training set)

and tested on 1068 No

molecules (test set)

10-fold CV: ACC=0.79 /

AUC=0.85

External: ACC=0.81 /

AUC=0.87

CYP3A4 inhibitor ⓘ

Cytochrome P450 3A4**inhibitor:** SVM model

built on 7518 molecules

(training set)

and tested on 2579 No

molecules (test set)

10-fold CV: ACC=0.77 /

AUC=0.85

External: ACC=0.78 /

AUC=0.86

Log K_p (skin
permeation) ⓘ**Skin permeation:**

QSPR model

implemented from

Potts RO and Guy RH.

1992 Pharm. Res.

-10.08 cm/s

Druglikeness

Lipinski ⓘ

Lipinski (Pfizer) filter:

implemented from

Lipinski CA. et al. 2001

Adv. Drug Deliv. Rev.

MW < 500

MLOGP < 4.15

N or O < 10

NH or OH < 5

Yes; 0 violation

Ghose ⓘ

Ghose filter:

implemented from

Ghose AK. et al. 1999 J.

Comb. Chem.

160 < MW < 480

-0.4 < WLOGP < 5.6

40 < MR < 130

20 < atoms < 70

No; 4 violations: MW<160,
WLOGP<-0.4, MR<40, #atoms<20

Veber ⓘ

Yes

Veber (GSK) filter:

implemented from

Veber DE. et al. 2002 J.

Med. Chem.

[Rotatable bonds < 10](#)
[TPSA < 140](#)

Egan

Egan (Pharmacia)

filter: [implemented](#)

[from](#) Yes

[Egan W.J. et al. 2000 J. Med. Chem.](#)

[WLOGP < 5.88](#)

[TPSA < 131.6](#)

Muegge

Muegge (Bayer) filter:

[implemented from](#)

[Muegge I. et al. 2001 J. Med. Chem.](#)

[200 < MW < 600](#)

[-2 < XLOGP < 5](#)

[TPSA < 150](#)

[Num. rings < 7](#)

[Num. carbon > 4](#)

[Num. heteroatoms > 1](#)

[Num. rotatable bonds < 15](#)

[15](#)

[H-bond acc. < 10](#)

[H-bond don. < 5](#)

No; 3 violations: MW<200, XLOGP3<-2, #C<5

Bioavailability Score

Abbott Bioavailability

Score: [Probability of F](#)

[> 10% in rat](#) 0.55

[implemented from](#)

[Martin Y.C. 2005 J. Med. Chem.](#)

[Med. Chem.](#)

Medicinal Chemistry

PAINS

Pan Assay Interference

Structures:

[implemented from](#) 0 alert

[Baell JB. & Holloway](#)

[GA. 2010 J. Med. Chem.](#)

[Chem.](#)

Brenk

Structural Alert:

[implemented from](#) 0 alert

[Brenk R. et al. 2008](#)

[ChemMedChem](#)

Leadlikeness

Leadlikeness:

[implemented from](#)

[Teague S.J. 1999 Angew. Chem. Int. Ed.](#)

[250 < MW < 350](#) No; 1 violation: MW<250

[XLOGP < 3.5](#)

[Num. rotatable bonds < 7](#)

[7](#)

Synthetic accessibility 2.18

Synthetic accessibility

score: [from 1 \(very](#)

[easy\) to 10 \(very](#)

[difficult\)](#)

[based on 1024](#)



[fragmental contributions](#)

[\(FP2\) modulated by size](#)

[and complexity penalties.](#)

trained on 12'782'590
molecules and tested on
40 external molecules
($r^2 = 0.94$)

Molecule 13



SMILES
S N[C@@H](C(=O)O)[C@@H](c1cnco1)O

Physicochemical Properties

Formula	C6H8N2O4
Molecular weight	172.14 g/mol
Num. heavy atoms	12
Num. arom. heavy atoms	5
Fraction Csp3	0.33
Num. rotatable bonds	3
Num. H-bond acceptors	6
Num. H-bond donors	3
Molar Refractivity	36.72
TPSA	

Topological Polar Surface Area:
Calculated from
Ertl P. et al. 2000 J. Med. Chem.

109.58 Å²

Lipophilicity

Log $P_{o/w}$ (iLOGP)

iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.

0.45

Log $P_{o/w}$ (XLOGP3)

XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry.

-4.07

Log $P_{o/w}$ (WLOGP)

WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

-1.20

Log S (ESOL)

ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.

Water Solubility

1.55

Solubility
Class

6.06e+03 mg/ml ; 3.52e+01 mol/l

Solubility class: Log S scale
Insoluble < -10 < Poorly
< -6 < Moderately < -4
< Soluble < -2 Very < 0
< Highly

Log S (Ali)

Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.

2.37

Solubility
Class

4.05e+04 mg/ml ; 2.35e+02 mol/l

Solubility class: Log S scale
Insoluble < -10 < Poorly
< -6 < Moderately < -4
< Soluble < -2 Very < 0
< Highly

Log S (SILICOS-IT)

SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, <http://www.silicos-it.com>

0.23

Solubility
Class

2.92e+02 mg/ml ; 1.69e+00 mol/l











Solubility class: Log S scale
Insoluble < -10 < Poorly
< -6 < Moderately < -4
< Soluble < -2 Very < 0
< Highly

Pharmacokinetics

GI absorption

Gastrointestinal absorption: according to the white of the BOILED-Egg

High

Log $P_{o/w}$ (MLOGP) **MLOGP:** [Topological method implemented from](#)[Moriguchi I. et al. 1992 Chem. Pharm. Bull.](#) -4.55
[Moriguchi I. et al. 1994 Chem. Pharm. Bull.](#)
[Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.](#)Log $P_{o/w}$ (SILICOS-IT) **SILICOS-IT:** [Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, <http://www.silicos-it.com>](#) -0.93Consensus Log $P_{o/w}$ **Consensus Log $P_{o/w}$:** -2.06
[Average of all five predictions](#)BBB permeant **BBB permeation:** [according to the yolk of the BOILED-Egg](#) NoP-gp substrate **P-glycoprotein substrate:** [SVM model built on 1033 molecules \(training set\) and tested on 415 molecules \(test set\). 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94](#) NoCYP1A2 inhibitor **Cytochrome P450 1A2 inhibitor:** [SVM model built on 9145 molecules \(training set\) and tested on 3000 molecules \(test set\). 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91](#) NoCYP2C19 inhibitor **Cytochrome P450 2C19 inhibitor:** [SVM model built on 9272 molecules \(training set\) and tested on 3000 molecules \(test set\). 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87](#) NoCYP2C9 inhibitor **Cytochrome P450 2C9 inhibitor:** [SVM model built on 5940 molecules \(training set\) and tested on 2075 molecules \(test set\). 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81](#) NoCYP2D6 inhibitor **Cytochrome P450 2D6 inhibitor:** [SVM model built on 3664 molecules \(training set\) and tested on 1068 molecules \(test set\). 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87](#) NoCYP3A4 inhibitor  No**Cytochrome P450 3A4 inhibitor:** [SVM model built on 7518 molecules \(training set\)](#)

and tested on 2579
 molecules (test set)
 10-fold CV: ACC=0.77 /
 AUC=0.85
 External: ACC=0.78 /
 AUC=0.86

Log K_p (skin
 permeation) ?

Skin permeation:

[QSPR model](#) -10.24 cm/s
 implemented from
[Potts RO and Guy RH.](#)
[1992 Pharm. Res.](#)

Druglikeness

Lipinski ?

Lipinski (Pfizer) filter:

implemented from
[Lipinski CA. et al. 2001](#)
[Adv. Drug Deliv. Rev.](#) Yes; 0 violation
 MW < 500
 MLOGP < 4.15
 N or O < 10
 NH or OH < 5

Ghose ?

Ghose filter:

implemented from
[Ghose AK. et al. 1999 J.](#)
[Comb. Chem.](#) No; 2 violations: WLOGP<-0.4,
 MR<40
 160 < MW < 480
 -0.4 < WLOGP < 5.6
 40 < MR < 130
 20 < atoms < 70

Veber ?

Veber (GSK) filter:

implemented from
[Veber DF. et al. 2002 J.](#) Yes
[Med. Chem.](#)
 Rotatable bonds < 10
 TPSA < 140

Egan ?


**Egan (Pharmacia)
 filter:** implemented

from
[Egan WJ. et al. 2000 J.](#) Yes
[Med. Chem.](#)
 WLOGP < 5.88
 TPSA < 131.6

Muegge ?

Muegge (Bayer) filter:

implemented from
[Muegge I. et al. 2001 J.](#)
[Med. Chem.](#)
 200 < MW < 600
 -2 < XLOGP < 5
 TPSA < 150 No; 2 violations: MW<200,
 XLOGP3<-2
 Num. rings < 7
 Num. carbon > 4
 Num. heteroatoms > 1
 Num. rotatable bonds <
 15
 H-bond acc. < 10
 H-bond don. < 5

Bioavailability Score **Abbott Bioavailability:**

Score: Probability of F
 > 10% in rat 0.55
 implemented from
 Martin YC. 2005 J.
 Med. Chem.

Medicinal Chemistry

PAINS **Pan Assay Interference**


Structures:
 implemented from 0 alert
 Baell JB. & Holloway
 GA. 2010 J. Med.
 Chem.

Brenk **Structural Alert:**


implemented from 0 alert
 Brenk R. et al. 2008
 ChemMedChem

Leadlikeness **Leadlikeness:**

implemented from
 Teague SJ. 1999 Angew.
 Chem. Int. Ed. No; 1 violation: MW<250
 250 < MW < 350
 XLOGP < 3.5
 Num. rotatable bonds <
 7

Synthetic accessibility **Synthetic accessibility**



score: from 1 (very
 easy) to 10 (very
 difficult)
 based on 1024
 fragmental contributions 3.13
 (FP2) modulated by size
 and complexity penalties,
 trained on 12'782'590
 molecules and tested on
 40 external molecules
 ($r^2 = 0.94$)

Molecule 14 


SMILES N[C@@H](C(=O)O)[C@H](c1cnco1)O

Physicochemical Properties

Formula C6H8N2O4
 Molecular weight 172.14 g/mol
 Num. heavy atoms 12

Log S (ESOL) 

**ESOL: Topological
 method implemented
 from**
 Delaney JS. 2004 J.
 Chem. Inf. Model.

Solubility
 Class 

**Solubility class: Log S
 scale**

Insoluble < -10 < Poorly
 < -6 < Moderately < -4
 < Soluble < -2 Very < 0
 < Highly


Water Solubility

1.55


6.06e+03 mg/ml ; 3.52e+01 mol/l

Num. arom. heavy atoms	5	Log <i>S</i> (Ali)	
Fraction Csp3	0.33	Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	2.37
Num. rotatable bonds	3		
Num. H-bond acceptors	6		
Num. H-bond donors	3		
Molar Refractivity	36.72	Solubility	4.05e+04 mg/ml ; 2.35e+02 mol/l
TPSA		Class	
Topological Polar Surface Area:		Solubility class: Log <i>S</i> scale	
Calculated from Ertl P. et al. 2000 J. Med. Chem.	109.58 Å ²	Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Highly soluble
	Lipophilicity		
Log <i>P</i> _{o/w} (iLOGP)		Log <i>S</i> (SILICOS-IT)	
iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	0.48	SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	0.23
Log <i>P</i> _{o/w} (XLOGP3)		Solubility	2.92e+02 mg/ml ; 1.69e+00 mol/l
XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry.	-4.07	Class	
Log <i>P</i> _{o/w} (WLOGP)		Solubility class: Log <i>S</i> scale	
WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	-1.20	Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log <i>P</i> _{o/w} (MLOGP)			
MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	-4.55		
Log <i>P</i> _{o/w} (SILICOS-IT)			
SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-0.93		
Consensus Log <i>P</i> _{o/w}			
Consensus Log <i>P</i>_{o/w}: Average of all five predictions	-2.06		
			Pharmacokinetics
		GI absorption	
		Gastrointestinal absorption: according to the white of the BOILED-Egg	High
		BBB permeant	
		BBB permeation: according to the yolk of the BOILED-Egg	No
		P-gp substrate	
		P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set). 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
		CYP1A2 inhibitor	No
		Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set). 10-fold CV: ACC=0.83 / AUC=0.90	


[External: ACC=0.84 / AUC=0.91](#)

CYP2C19 inhibitor 


Cytochrome P450 2C19 inhibitor: SVM model built on [9272 molecules \(training set\)](#) and tested on [3000 molecules \(test set\)](#) No
 10-fold CV: ACC=0.80 / AUC=0.86
 External: ACC=0.80 / AUC=0.87

CYP2C9 inhibitor 


Cytochrome P450 2C9 inhibitor: SVM model built on [5940 molecules \(training set\)](#) and tested on [2075 molecules \(test set\)](#) No
 10-fold CV: ACC=0.78 / AUC=0.85
 External: ACC=0.71 / AUC=0.81

CYP2D6 inhibitor 

Cytochrome P450 2D6 inhibitor: SVM model built on [3664 molecules \(training set\)](#) and tested on [1068 molecules \(test set\)](#) No
 10-fold CV: ACC=0.79 / AUC=0.85
 External: ACC=0.81 / AUC=0.87

CYP3A4 inhibitor 

Cytochrome P450 3A4 inhibitor: SVM model built on [7518 molecules \(training set\)](#) and tested on [2579 molecules \(test set\)](#) No
 10-fold CV: ACC=0.77 / AUC=0.85
 External: ACC=0.78 / AUC=0.86

Log K_p (skin permeation) 

Skin permeation: QSPR model implemented from [Potts RO and Guy RH. 1992 Pharm. Res.](#) -10.24 cm/s

Druglikeness

Lipinski 

Lipinski (Pfizer) filter: implemented from [Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.](#) Yes; 0 violation
 MW < 500
 MLOGP < 4.15
 N or O < 10
 NH or OH < 5

Ghose **Ghose filter:**

implemented from

[Ghose AK. et al. 1999 J.](#)[Comb. Chem.](#)[160 < MW < 480](#)[-0.4 < WLOGP < 5.6](#)[40 < MR < 130](#)[20 < atoms < 70](#)No; 2 violations: WLOGP<-0.4,
MR<40Veber **Veber (GSK) filter:**

implemented from

[Veber DF. et al. 2002 J.](#)[Med. Chem.](#)[Rotatable bonds < 10](#)[TPSA < 140](#)


Yes

Egan **Egan (Pharmacia)****filter:** implemented

from

[Egan WJ. et al. 2000 J.](#)[Med. Chem.](#)[WLOGP < 5.88](#)[TPSA < 131.6](#)

Yes

Muegge **Muegge (Bayer) filter:**

implemented from

[Muegge I. et al. 2001 J.](#)[Med. Chem.](#)[200 < MW < 600](#)[-2 < XLOGP < 5](#)[TPSA < 150](#)[Num. rings < 7](#)[Num. carbon > 4](#)[Num. heteroatoms > 1](#)[Num. rotatable bonds <](#)[15](#)[H-bond acc. < 10](#)[H-bond don. < 5](#)No; 2 violations: MW<200,
XLOGP3<-2Bioavailability Score **Abbott Bioavailability****Score:** Probability of F[> 10% in rat](#)

implemented from

[Martin YC. 2005 J.](#)[Med. Chem.](#)

0.55

Medicinal Chemistry

PAINS **Pan Assay Interference****Structures:**

implemented from

[Baell JB. & Holloway.](#)[GA. 2010 J. Med.](#)[Chem.](#)

0 alert

Brenk **Structural Alert:**

implemented from

[Brenk R. et al. 2008](#)[ChemMedChem](#)

0 alert

Leadlikeness 

No; 1 violation: MW<250

Leadlikeness:

implemented from



[Teague SJ. 1999 Angew. Chem. Int. Ed.](#)
[250 < MW < 350](#)
[XLOGP < 3.5](#)
[Num. rotatable bonds < 7](#)

Synthetic accessibility

Synthetic accessibility

score: from 1 (very easy) to 10 (very difficult)
 based on 1024 fragmental contributions 3.13
 (FP2) modulated by size and complexity penalties, trained on 12'782'590 molecules and tested on 40 external molecules
 ($r^2 = 0.94$)

Molecule 15



SMILES OC(=O)[C@H](F)[C@H](N)C(=O)N

Physicochemical Properties

Formula	C4H7FN2O3
Molecular weight	150.11 g/mol
Num. heavy atoms	10
Num. arom. heavy atoms	0
Fraction Csp3	0.50
Num. rotatable bonds	3
Num. H-bond acceptors	5
Num. H-bond donors	3
Molar Refractivity	28.78
TPSA	

Topological Polar Surface Area:

Surface Area: 106.41 Å²
 Calculated from [Ertl P. et al. 2000 J. Med. Chem.](#)

Lipophilicity

Log $P_{o/w}$ (iLOGP)

iLOGP: in-house physics-based method implemented from [Daina A et al. 2014 J. Chem. Inf. Model.](#) -0.24

Log $P_{o/w}$ (XLOGP3) -4.04

XLOGP3: Atomistic and knowledge-based

Log S (ESOL)

ESOL: Topological method implemented from [Delaney JS. 2004 J. Chem. Inf. Model.](#)

Water Solubility

1.97

Solubility Class

1.41e+04 mg/ml ; 9.39e+01 mol/l

Solubility class: Log S scale

Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Log S (Ali)

Ali: Topological method implemented from [Ali J. et al. 2012 J. Chem. Inf. Model.](#)

2.41

Solubility Class

3.83e+04 mg/ml ; 2.55e+02 mol/l

Solubility class: Log S scale

Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Log S (SILICOS-IT)

SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, <http://www.silicos-it.com>

1.16

Solubility

2.15e+03 mg/ml ; 1.44e+01 mol/l

[method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry.](#)

Log $P_{o/w}$ (WLOGP) [?]

WLOGP: Atomistic method implemented from

-1.36

[Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.](#)

Log $P_{o/w}$ (MLOGP) [?]

MLOGP: Topological method implemented from

-3.78

[Moriguchi I. et al. 1992 Chem. Pharm. Bull.](#)
[Moriguchi I. et al. 1994 Chem. Pharm. Bull.](#)
[Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.](#)

Log $P_{o/w}$ (SILICOS-IT) [?]

SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, <http://www.silicos-it.com>

-1.46

Consensus Log $P_{o/w}$ [?]

Consensus Log $P_{o/w}$: Average of all five predictions

-2.18

Class [?]

Solubility class: Log S scale

[Insoluble < -10 < Poorly Soluble < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly](#)

Pharmacokinetics

GI absorption [?]

Gastrointestinal absorption: according to the white of the BOILED-Egg High

BBB permeant [?]

BBB permeation: according to the yolk of the BOILED-Egg No

P-gp substrate [?]

P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set). No
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

CYP1A2 inhibitor [?]

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set). No
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

CYP2C19 inhibitor [?]

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set). No
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

CYP2C9 inhibitor [?]

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set). No
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

CYP2D6 inhibitor ?

Cytochrome P450 2D6**inhibitor:** [SVM model](#)[built on 3664 molecules](#)[\(training set\)](#)

and tested on 1068 No

[molecules \(test set\)](#)

10-fold CV: ACC=0.79 /

AUC=0.85

External: ACC=0.81 /

AUC=0.87

CYP3A4 inhibitor ?

Cytochrome P450 3A4**inhibitor:** [SVM model](#)[built on 7518 molecules](#)[\(training set\)](#)

and tested on 2579 No

[molecules \(test set\)](#)

10-fold CV: ACC=0.77 /

AUC=0.85

External: ACC=0.78 /

AUC=0.86

Log K_p (skin permeation) ?**Skin permeation:**[QSPR model](#)

-10.08 cm/s

[implemented from](#)[Potts RO and Guy RH.](#)[1992 Pharm. Res.](#)

Druglikeness

Lipinski ?

Lipinski (Pfizer) filter:[implemented from](#)[Lipinski CA. et al. 2001](#)[Adv. Drug Deliv. Rev.](#)

Yes; 0 violation

[MW < 500](#)[MLOGP < 4.15](#)[N or O < 10](#)[NH or OH < 5](#)

Ghose ?

Ghose filter:[implemented from](#)[Ghose AK. et al. 1999 J.](#)[Comb. Chem.](#)No; 4 violations: MW<160,
WLOGP<-0.4, MR<40, #atoms<20[160 < MW < 480](#)[-0.4 < WLOGP < 5.6](#)[40 < MR < 130](#)[20 < atoms < 70](#)

Veber ?

Veber (GSK) filter:[implemented from](#)[Veber DF. et al. 2002 J.](#)[Med. Chem.](#)

Yes


[Rotatable bonds < 10](#)[TPSA < 140](#)

Egan ?


Egan (Pharmacia)**filter:** [implemented](#)[from](#)[Egan WJ. et al. 2000 J.](#)[Med. Chem.](#)

Yes

[WLOGP < 5.88](#)[TPSA < 131.6](#)

Muegge **Muegge (Bayer) filter:**

implemented from

[Muegge I. et al. 2001 J.](#)[Med. Chem.](#)[200 < MW < 600](#)[-2 < XLOGP < 5](#)[TPSA < 150](#)[Num. rings < 7](#)[Num. carbon > 4](#)[Num. heteroatoms > 1](#)[Num. rotatable bonds <](#)[15](#)[H-bond acc. < 10](#)[H-bond don. < 5](#)No; 3 violations: MW<200,
XLOGP3<-2, #C<5Bioavailability Score **Abbott Bioavailability****Score: Probability of F**[> 10% in rat](#)

0.55

implemented from

[Martin YC. 2005 J.](#)[Med. Chem.](#)

Medicinal Chemistry

PAINS **Pan Assay Interference****Structures:**

implemented from

0 alert

[Baell JB. & Holloway](#)[GA. 2010 J. Med.](#)[Chem.](#)Brenk **Structural Alert:**

implemented from


0 alert

[Brenk R. et al. 2008](#)[ChemMedChem](#)Leadlikeness **Leadlikeness:**

implemented from

[Teague SJ. 1999 Angew.](#)[Chem. Int. Ed.](#)

No; 1 violation: MW<250

[250 < MW < 350](#)[XLOGP < 3.5](#)[Num. rotatable bonds <](#)[7](#)Synthetic accessibility **Synthetic accessibility****score: from 1 (very****easy) to 10 (very****difficult)**

based on 1024



[fragmental contributions](#) 2.18[\(FP2\) modulated by size](#)[and complexity penalties,](#)[trained on 12'782'590](#)[molecules and tested on](#)[40 external molecules](#)[\(r² = 0.94\)](#)

Molecule 16



Water Solubility





SMILES N[C@@H]1CON(C1=O)CCCO

Physicochemical Properties

Formula	C6H12N2O3
Molecular weight	160.17 g/mol
Num. heavy atoms	11
Num. arom. heavy atoms	0
Fraction Csp3	0.83
Num. rotatable bonds	3
Num. H-bond acceptors	4
Num. H-bond donors	2
Molar Refractivity	40.81
TPSA	

Topological Polar Surface Area: 75.79 Å²
 Calculated from Ertl P. et al. 2000 J. Med. Chem.

Lipophilicity
 Log $P_{o/w}$ (iLOGP)

iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model. 1.16

Log $P_{o/w}$ (XLOGP3)
XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry. -1.66

Log $P_{o/w}$ (WLOGP)
WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model. -1.91

Log $P_{o/w}$ (MLOGP)
MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. -1.27

Log S (ESOL)

ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model. 0.41

Solubility Class 4.12e+02 mg/ml ; 2.57e+00 mol/l

Solubility class: Log S scale
 Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Log S (Ali)

Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model. 0.58

Solubility Class 6.09e+02 mg/ml ; 3.80e+00 mol/l

Solubility class: Log S scale
 Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Log S (SILICOS-IT)

SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, <http://www.silicos-it.com> 0.29

Solubility Class 3.09e+02 mg/ml ; 1.93e+00 mol/l

Solubility class: Log S scale
 Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Pharmacokinetics

GI absorption
Gastrointestinal absorption: according to the white of the BOILED-Egg High


BBB permeant
BBB permeation: according to the yolk of the BOILED-Egg No

P-gp substrate No


P-glycoprotein substrate: SVM model built on 1033 molecules

[Lipinski PA. et al. 2001
Adv. Drug. Deliv. Rev.](#)
Log $P_{o/w}$ (SILICOS-IT)


SILICOS-IT: Hybrid
fragmental/topological
method calculated by
FILTER-IT program, -0.86
version 1.0.2, courtesy
of SILICOS-IT,
[http://www.silicos-
it.com](http://www.silicos-
it.com)

Consensus Log $P_{o/w}$ 


Consensus Log $P_{o/w}$: -0.91
[Average of all five
predictions](#)

(training set)
and tested on 415
molecules (test set)
10-fold CV: ACC=0.72 /
AUC=0.77
External: ACC=0.88 /
AUC=0.94
CYP1A2 inhibitor 


**Cytochrome P450 1A2
inhibitor:** SVM model
built on 9145 molecules
(training set)
and tested on 3000 No
molecules (test set)
10-fold CV: ACC=0.83 /
AUC=0.90
External: ACC=0.84 /
AUC=0.91

CYP2C19 inhibitor 


**Cytochrome P450
2C19 inhibitor:** SVM
model built on 9272
molecules (training set)
and tested on 3000 No
molecules (test set)
10-fold CV: ACC=0.80 /
AUC=0.86
External: ACC=0.80 /
AUC=0.87

CYP2C9 inhibitor 

**Cytochrome P450 2C9
inhibitor:** SVM model
built on 5940 molecules
(training set)
and tested on 2075 No
molecules (test set)
10-fold CV: ACC=0.78 /
AUC=0.85
External: ACC=0.71 /
AUC=0.81

CYP2D6 inhibitor 

**Cytochrome P450 2D6
inhibitor:** SVM model
built on 3664 molecules
(training set)
and tested on 1068 No
molecules (test set)
10-fold CV: ACC=0.79 /
AUC=0.85
External: ACC=0.81 /
AUC=0.87

CYP3A4 inhibitor 

**Cytochrome P450 3A4
inhibitor:** SVM model
built on 7518 molecules
(training set)
and tested on 2579 No
molecules (test set)
10-fold CV: ACC=0.77 /
AUC=0.85
External: ACC=0.78 /
AUC=0.86

Log K_p (skin
permeation)  -8.46 cm/s

Skin permeation:
QSPR model

[implemented from Potts RO and Guy RH. 1992 Pharm. Res.](#)

Druglikeness

Lipinski [?]

Lipinski (Pfizer) filter:

[implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.](#)
[MW < 500](#)
[MLOGP < 4.15](#)
[N or O < 10](#)
[NH or OH < 5](#)

Yes; 0 violation

Ghose [?]

Ghose filter:

[implemented from Ghose AK. et al. 1999 J. Comb. Chem.](#)
[160 < MW < 480](#)
[-0.4 < WLOGP < 5.6](#)
[40 < MR < 130](#)
[20 < atoms < 70](#)

No; 1 violation: WLOGP < -0.4

Veber [?]

Veber (GSK) filter:

[implemented from Veber DF. et al. 2002 J. Med. Chem.](#)
[Rotatable bonds < 10](#)
[TPSA < 140](#)

Yes

Egan [?]

Egan (Pharmacia) filter:

[implemented from Egan WJ. et al. 2000 J. Med. Chem.](#)
[WLOGP < 5.88](#)
[TPSA < 131.6](#)

Yes

Muegge [?]

Muegge (Bayer) filter:

[implemented from Muegge I. et al. 2001 J. Med. Chem.](#)
[200 < MW < 600](#)
[-2 < XLOGP < 5](#)
[TPSA < 150](#)
[Num. rings < 7](#)
[Num. carbon > 4](#)
[Num. heteroatoms > 1](#)
[Num. rotatable bonds < 15](#)
[H-bond acc. < 10](#)
[H-bond don. < 5](#)

No; 1 violation: MW < 200

Bioavailability Score [?]

Abbott Bioavailability

Score: Probability of F
[> 10% in rat](#)
[implemented from Martin YC. 2005 J. Med. Chem.](#)

0.55

Medicinal Chemistry

PAINS [?]

0 alert

Pan Assay Interference Structures:

[implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.](#)

Brenk

Structural Alert:

[implemented from Brenk R. et al. 2008 ChemMedChem](#) 0 alert

Leadlikeness

Leadlikeness:



[implemented from Teague SJ. 1999 Angew. Chem. Int. Ed.](#) No; 1 violation: MW<250
[250 < MW < 350](#)
[XLOGP < 3.5](#)
[Num. rotatable bonds < 7](#)

Synthetic accessibility

Synthetic accessibility

score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penalties, trained on 12'782'590 molecules and tested on 40 external molecules ($r^2 = 0.94$) 3.17

Molecule 17



SMILES NC1CON(C(=O)CCCCO)C1=O

Physicochemical Properties

Formula C6H12N2O3
 Molecular weight 160.17 g/mol
 Num. heavy atoms 11
 Num. arom. heavy atoms 0
 Fraction Csp3 0.83
 Num. rotatable bonds 3
 Num. H-bond acceptors 4
 Num. H-bond donors 2
 Molar Refractivity 40.81
 TPSA 75.79 Å²

Topological Polar

Surface Area:
[Calculated from](#)

Log S (ESOL)

ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.

Water Solubility

0.41

Solubility Class

4.12e+02 mg/ml ; 2.57e+00 mol/l

Solubility class: Log S scale
 Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Log S (Ali)

Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.

0.58

Solubility Class

6.09e+02 mg/ml ; 3.80e+00 mol/l Highly soluble

Solubility class: Log S scale
 Insoluble < -10 < Poorly < -6 < Moderately < -4

Ertl P. et al. 2000 J. Med. Chem.		< Soluble < -2 Very < 0 < Highly	
Log $P_{o/w}$ (iLOGP)	Lipophilicity	Log S (SILICOS-IT)	
iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	1.16	SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	0.29
Log $P_{o/w}$ (XLOGP3)		Solubility Class	3.09e+02 mg/ml ; 1.93e+00 mol/l
XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry.	-1.66	Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log $P_{o/w}$ (WLOGP)			Pharmacokinetics
WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	-1.91	GI absorption	
Log $P_{o/w}$ (MLOGP)		Gastrointestinal absorption: according to the white of the BOILED-Egg	High
MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	-1.27	BBB permeant	
Log $P_{o/w}$ (SILICOS-IT)		BBB permeation: according to the yolk of the BOILED-Egg	No
SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-0.86	P-gp substrate	
Consensus Log $P_{o/w}$		P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set). 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
Consensus Log $P_{o/w}$: Average of all five predictions	-0.91	CYP1A2 inhibitor	
		Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set). 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	No
		CYP2C19 inhibitor	
		Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set). 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No

CYP2C9 inhibitor ⓘ

Cytochrome P450 2C9**inhibitor:** SVM model

built on 5940 molecules

(training set)

and tested on 2075 No

molecules (test set)

10-fold CV: ACC=0.78 /

AUC=0.85

External: ACC=0.71 /

AUC=0.81

CYP2D6 inhibitor ⓘ

Cytochrome P450 2D6**inhibitor:** SVM model

built on 3664 molecules

(training set)

and tested on 1068 No

molecules (test set)

10-fold CV: ACC=0.79 /

AUC=0.85

External: ACC=0.81 /

AUC=0.87

CYP3A4 inhibitor ⓘ

Cytochrome P450 3A4**inhibitor:** SVM model

built on 7518 molecules

(training set)

and tested on 2579 No

molecules (test set)

10-fold CV: ACC=0.77 /

AUC=0.85

External: ACC=0.78 /

AUC=0.86

Log K_p (skin
permeation) ⓘ**Skin permeation:**

QSPR model

-8.46 cm/s

implemented from

Potts RO and Guy RH.

1992 Pharm. Res.

Druglikeness

Lipinski ⓘ

Lipinski (Pfizer) filter:

implemented from

Lipinski CA. et al. 2001

Adv. Drug Deliv. Rev. Yes; 0 violation

MW < 500

MLOGP < 4.15

N or O < 10

NH or OH < 5

Ghose ⓘ

Ghose filter:

implemented from

Ghose AK. et al. 1999 J.

Comb. Chem.

No; 1 violation: WLOGP < -0.4

160 < MW < 480

-0.4 < WLOGP < 5.6

40 < MR < 130

20 < atoms < 70

Veber ⓘ

Yes

Veber (GSK) filter:

implemented from

Veber DE. et al. 2002 J.

Med. Chem.

[Rotatable bonds < 10](#)
[TPSA < 140](#)

Egan

Egan (Pharmacia)

filter: [implemented](#)

[from](#) Yes

[Egan W.J. et al. 2000 J. Med. Chem.](#)

[WLOGP < 5.88](#)

[TPSA < 131.6](#)

Muegge

Muegge (Bayer) filter:

[implemented from](#)

[Muegge I. et al. 2001 J. Med. Chem.](#)

[200 < MW < 600](#)

[-2 < XLOGP < 5](#)

[TPSA < 150](#) No; 1 violation: MW<200

[Num. rings < 7](#)

[Num. carbon > 4](#)

[Num. heteroatoms > 1](#)

[Num. rotatable bonds < 15](#)

[15](#)

[H-bond acc. < 10](#)

[H-bond don. < 5](#)

Bioavailability Score

Abbott Bioavailability

Score: [Probability of F](#) 0.55

[> 10% in rat](#)

[implemented from](#)

[Martin Y.C. 2005 J. Med. Chem.](#)

[Med. Chem.](#)

Medicinal Chemistry

PAINS

Pan Assay Interference

Structures:

[implemented from](#) 0 alert

[Baell JB. & Holloway](#)

[GA. 2010 J. Med. Chem.](#)

[Chem.](#)

Brenk

Structural Alert:

[implemented from](#) 0 alert

[Brenk R. et al. 2008](#)

[ChemMedChem](#)

Leadlikeness

Leadlikeness:

[implemented from](#)

[Teague S.J. 1999 Angew. Chem. Int. Ed.](#)

[250 < MW < 350](#) No; 1 violation: MW<250

[XLOGP < 3.5](#)

[Num. rotatable bonds < 7](#)

[7](#)

Synthetic accessibility 3.17

Synthetic accessibility

score: [from 1 \(very](#)

[easy\) to 10 \(very](#)

[difficult\)](#)

[based on 1024](#)



[fragmental contributions](#)

[\(FP2\) modulated by size](#)

[and complexity penalties.](#)

trained on 12'782'590
molecules and tested on
40 external molecules
($r^2 = 0.94$)

Molecule 18



SMILE OC(=O)[C@@H](C(=C(F)F)F)N
S

Physicochemical Properties

Formula	C4H4F3NO2
Molecular weight	155.08 g/mol
Num. heavy atoms	10
Num. arom. heavy atoms	0
Fraction Csp3	0.25
Num. rotatable bonds	2
Num. H-bond acceptors	6
Num. H-bond donors	2
Molar Refractivity	25.50
TPSA	

Topological Polar Surface Area: 63.32 Å²
Calculated from Ertl P. et al. 2000 J. Med. Chem.

Lipophilicity
Log $P_{o/w}$ (iLOGP)

iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model. 0.87

Log $P_{o/w}$ (XLOGP3)

XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry. -2.60

Log $P_{o/w}$ (WLOGP)

WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model. 1.74

Log S (ESOL)

ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model. 0.97

Solubility Class 1.44e+03 mg/ml ; 9.30e+00 mol/l

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly Highly soluble

Log S (Ali)

Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model. 1.82

Solubility Class 1.02e+04 mg/ml ; 6.56e+01 mol/l

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly Highly soluble

Log S (SILICOS-IT)

SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, <http://www.silicos-it.com> 0.14

Solubility Class 2.16e+02 mg/ml ; 1.39e+00 mol/l


Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly Soluble

Water Solubility


Pharmacokinetics

GI absorption


Gastrointestinal absorption: according to the white of the BOILED-Egg High

Log $P_{o/w}$ (MLOGP) **MLOGP: Topological method implemented from**


[Moriguchi I. et al. 1992 Chem. Pharm. Bull.](#) -2.12
[Moriguchi I. et al. 1994 Chem. Pharm. Bull.](#)
[Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.](#)

Log $P_{o/w}$ (SILICOS-IT) **SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, <http://www.silicos-it.com>**


0.11

Consensus Log $P_{o/w}$ **Consensus Log $P_{o/w}$: Average of all five predictions**


-0.40

BBB permeant **BBB permeation: according to the yolk of the BOILED-Egg**


Yes

P-gp substrate **P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set). 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94**


No

CYP1A2 inhibitor **Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set). 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91**


No

CYP2C19 inhibitor **Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set). 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87**


No

CYP2C9 inhibitor **Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set). 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81**

No


CYP2D6 inhibitor **Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set). 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87**

No

CYP3A4 inhibitor **Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set).**

No

and tested on 2579
 molecules (test set)
 10-fold CV: ACC=0.77 /
 AUC=0.85
 External: ACC=0.78 /
 AUC=0.86

Log K_p (skin
 permeation) 

Skin permeation:

[QSPR model](#) -9.09 cm/s
 implemented from
[Potts RO and Guy RH.](#)
[1992 Pharm. Res.](#)

Druglikeness

Lipinski 

Lipinski (Pfizer) filter:

implemented from
[Lipinski CA. et al. 2001](#)
[Adv. Drug Deliv. Rev.](#) Yes; 0 violation
 MW < 500
 MLOGP < 4.15
 N or O < 10
 NH or OH < 5

Ghose 

Ghose filter:

implemented from
[Ghose AK. et al. 1999 J.](#)
[Comb. Chem.](#) No; 3 violations: MW<160, MR<40,
 #atoms<20
 160 < MW < 480
 -0.4 < WLOGP < 5.6
 40 < MR < 130
 20 < atoms < 70

Veber 


Veber (GSK) filter:

implemented from
[Veber DF. et al. 2002 J.](#) Yes
[Med. Chem.](#)
 Rotatable bonds < 10
 TPSA < 140

Egan 


**Egan (Pharmacia)
 filter:** implemented

from
[Egan WJ. et al. 2000 J.](#) Yes
[Med. Chem.](#)
 WLOGP < 5.88
 TPSA < 131.6

Muegge 

Muegge (Bayer) filter:

implemented from
[Muegge I. et al. 2001 J.](#)
[Med. Chem.](#) No; 3 violations: MW<200,
 XLOGP3<-2, #C<5
 200 < MW < 600
 -2 < XLOGP < 5
 TPSA < 150
 Num. rings < 7
 Num. carbon > 4
 Num. heteroatoms > 1
 Num. rotatable bonds <
 15
 H-bond acc. < 10
 H-bond don. < 5

Bioavailability Score **Abbott Bioavailability:**

Score: Probability of F
 > 10% in rat 0.55
 implemented from
 Martin YC. 2005 J.
 Med. Chem.

Medicinal Chemistry

PAINS **Pan Assay Interference**


Structures:
 implemented from 0 alert
 Baell JB. & Holloway
 GA. 2010 J. Med.
 Chem.

Brenk **Structural Alert:**

implemented from 0 alert
 Brenk R. et al. 2008
 ChemMedChem




Leadlikeness **Leadlikeness:**

implemented from
 Teague SJ. 1999 Angew.
 Chem. Int. Ed. No; 1 violation: MW<250
 250 < MW < 350
 XLOGP < 3.5
 Num. rotatable bonds <
 7

Synthetic accessibility **Synthetic accessibility**

score: from 1 (very
 easy) to 10 (very
 difficult)
 based on 1024
 fragmental contributions 2.34
 (FP2) modulated by size
 and complexity penalties,
 trained on 12'782'590
 molecules and tested on
 40 external molecules
 ($r^2 = 0.94$)


Molecule 19

Log S (ESOL) 

ESOL: Topological
 method implemented
 from
 Delaney JS. 2004 J.
 Chem. Inf. Model.

Water Solubility

1.96

Solubility
 Class 

1.47e+04 mg/ml ; 9.21e+01 mol/l

Solubility class: Log S
 scale

Insoluble < -10 < Poorly
 < -6 < Moderately < -4
 < Soluble < -2 Very < 0
 < Highly


SMILES
 S OC(=O)C[C@H]1ONC(=O)[C@H]1N

Physicochemical Properties


Formula C5H8N2O4
 Molecular weight 160.13 g/mol
 Num. heavy atoms 11

Num. arom. heavy atoms	0	Log <i>S</i> (Ali)	
Fraction Csp3	0.60	Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	2.70
Num. rotatable bonds	2		
Num. H-bond acceptors	5		
Num. H-bond donors	3		
Molar Refractivity	36.52	Solubility Class	8.09e+04 mg/ml ; 5.05e+02 mol/l
TPSA		Solubility class: Log <i>S</i> scale	
Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	101.65 Å ²	Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Highly soluble
	Lipophilicity		
Log <i>P</i> _{o/w} (iLOGP)		Log <i>S</i> (SILICOS-IT)	
iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	0.35	SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	0.66
Log <i>P</i> _{o/w} (XLOGP3)		Solubility Class	7.35e+02 mg/ml ; 4.59e+00 mol/l
XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry.	-4.23	Solubility class: Log <i>S</i> scale	Soluble
Log <i>P</i> _{o/w} (WLOGP)		Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	
WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	-2.16		Pharmacokinetics
Log <i>P</i> _{o/w} (MLOGP)		GI absorption	
MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	-1.76	Gastrointestinal absorption: according to the white of the BOILED-Egg	High
Log <i>P</i> _{o/w} (SILICOS-IT)		BBB permeant	
SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-1.39	BBB permeation: according to the yolk of the BOILED-Egg	No
Consensus Log <i>P</i> _{o/w}		P-gp substrate	
Consensus Log <i>P</i>_{o/w}: Average of all five predictions	-1.84	P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set). 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
		CYP1A2 inhibitor	No
		Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set). 10-fold CV: ACC=0.83 / AUC=0.90	


[External: ACC=0.84 / AUC=0.91](#)

CYP2C19 inhibitor 


Cytochrome P450 2C19 inhibitor: SVM model built on [9272 molecules \(training set\)](#) and tested on [3000 molecules \(test set\)](#) No
 10-fold CV: ACC=0.80 / AUC=0.86
 External: ACC=0.80 / AUC=0.87

CYP2C9 inhibitor 


Cytochrome P450 2C9 inhibitor: SVM model built on [5940 molecules \(training set\)](#) and tested on [2075 molecules \(test set\)](#) No
 10-fold CV: ACC=0.78 / AUC=0.85
 External: ACC=0.71 / AUC=0.81

CYP2D6 inhibitor 

Cytochrome P450 2D6 inhibitor: SVM model built on [3664 molecules \(training set\)](#) and tested on [1068 molecules \(test set\)](#) No
 10-fold CV: ACC=0.79 / AUC=0.85
 External: ACC=0.81 / AUC=0.87


CYP3A4 inhibitor 

Cytochrome P450 3A4 inhibitor: SVM model built on [7518 molecules \(training set\)](#) and tested on [2579 molecules \(test set\)](#) No
 10-fold CV: ACC=0.77 / AUC=0.85
 External: ACC=0.78 / AUC=0.86

Log K_p (skin permeation) 

Skin permeation: QSPR model implemented from [Potts RO and Guy RH. 1992 Pharm. Res.](#) -10.28 cm/s

Druglikeness

Lipinski 

Lipinski (Pfizer) filter: implemented from [Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.](#) Yes; 0 violation
 MW < 500
 MLOGP < 4.15
 N or O < 10
 NH or OH < 5

Ghose **Ghose filter:**

implemented from

[Ghose AK. et al. 1999 J. Comb. Chem.](#)[160 < MW < 480](#)[-0.4 < WLOGP < 5.6](#)[40 < MR < 130](#)[20 < atoms < 70](#)No; 3 violations: WLOGP<-0.4,
MR<40, #atoms<20Veber **Veber (GSK) filter:**

implemented from

[Veber DF. et al. 2002 J. Med. Chem.](#)[Rotatable bonds < 10](#)[TPSA < 140](#)


Yes

Egan **Egan (Pharmacia)****filter:** implemented

from

[Egan WJ. et al. 2000 J. Med. Chem.](#)[WLOGP < 5.88](#)[TPSA < 131.6](#)

Yes

Muegge **Muegge (Bayer) filter:**

implemented from

[Muegge I. et al. 2001 J. Med. Chem.](#)[200 < MW < 600](#)[-2 < XLOGP < 5](#)[TPSA < 150](#)[Num. rings < 7](#)[Num. carbon > 4](#)[Num. heteroatoms > 1](#)[Num. rotatable bonds < 15](#)[H-bond acc. < 10](#)[H-bond don. < 5](#)No; 2 violations: MW<200,
XLOGP3<-2Bioavailability Score **Abbott Bioavailability****Score:** Probability of F[> 10% in rat](#)

implemented from

[Martin YC. 2005 J. Med. Chem.](#)[Med. Chem.](#)

0.55

Medicinal Chemistry

PAINS **Pan Assay Interference****Structures:**

implemented from

[Baell JB. & Holloway. GA. 2010 J. Med. Chem.](#)

0 alert

Brenk **Structural Alert:**

implemented from

[Brenk R. et al. 2008 ChemMedChem](#)

0 alert

Leadlikeness 

No; 1 violation: MW<250

Leadlikeness:

implemented from



Teague SJ. 1999 Angew.
Chem. Int. Ed.
250 < MW < 350
XLOGP < 3.5
Num. rotatable bonds <
7

Synthetic accessibility [?]

Synthetic accessibility

score: from 1 (very
easy) to 10 (very
difficult)
based on 1024
fragmental contributions 3.42
(FP2) modulated by size
and complexity penalties,
trained on 12'782'590
molecules and tested on
40 external molecules
($r^2 = 0.94$)

Molecule 20



Log *S* (ESOL) [?]

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

Water Solubility

1.96

Solubility Class [?]

1.47e+04 mg/ml ; 9.21e+01 mol/l

Solubility class: Log *S* scale
Insoluble < -10 < Poorly
< -6 < Moderately < -4
< Soluble < -2 Very < 0
< Highly

Highly soluble

SMILES OC(=O)C[C@H]1ONC(=O)[C@@H]1N

Physicochemical Properties

Formula C5H8N2O4
Molecular weight 160.13 g/mol
Num. heavy atoms 11
Num. arom. heavy atoms 0
Fraction Csp3 0.60
Num. rotatable bonds 2
Num. H-bond acceptors 5
Num. H-bond donors 3
Molar Refractivity 36.52
TPSA [?]

Topological Polar Surface Area:
Calculated from
Ertl P. et al. 2000 J. Med. Chem.

101.65 Å²

Log *S* (Ali) [?]

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

2.70

Solubility Class [?]

8.09e+04 mg/ml ; 5.05e+02 mol/l

Solubility class: Log *S* scale
Insoluble < -10 < Poorly
< -6 < Moderately < -4
< Soluble < -2 Very < 0
< Highly

Highly soluble

Lipophilicity

Log *P*_{o/w} (iLOGP) [?]

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

0.16

Log *S* (SILICOS-IT) [?]

SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT.
<http://www.silicos-it.com>

0.66

Log *P*_{o/w} (XLOGP3) [?] -4.23

XLOGP3: Atomistic and knowledge-based

Solubility

7.35e+02 mg/ml ; 4.59e+00 mol/l

[method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry.](#)

Log $P_{o/w}$ (WLOGP) [?]

WLOGP: Atomistic method implemented from

[Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.](#)

-2.16

Log $P_{o/w}$ (MLOGP) [?]

MLOGP: Topological method implemented from

[Moriguchi I. et al. 1992 Chem. Pharm. Bull.](#)

[Moriguchi I. et al. 1994 Chem. Pharm. Bull.](#)

[Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.](#)

-1.76

Log $P_{o/w}$ (SILICOS-IT) [?]

SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, <http://www.silicos-it.com>

-1.39

Consensus Log $P_{o/w}$ [?]

Consensus Log $P_{o/w}$: Average of all five predictions

-1.88

Class [?]

Solubility class: Log S

scale

[Insoluble < -10 < Poorly Soluble](#)

[< -6 < Moderately < -4](#)

[< Soluble < -2 Very < 0](#)

[< Highly](#)

Pharmacokinetics

GI absorption [?]

Gastrointestinal absorption: according to the white of the BOILED-Egg High

BBB permeant [?]

BBB permeation: according to the yolk of the BOILED-Egg No

P-gp substrate [?]

P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set). No
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

CYP1A2 inhibitor [?]


Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set). No
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

CYP2C19 inhibitor [?]

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set). No
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

CYP2C9 inhibitor [?]

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set). No
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

CYP2D6 inhibitor **Cytochrome P450 2D6****inhibitor:** [SVM model](#)[built on 3664 molecules](#)[\(training set\)](#)


and tested on 1068 No

[molecules \(test set\)](#)

10-fold CV: ACC=0.79 /

[AUC=0.85](#)

External: ACC=0.81 /

[AUC=0.87](#)CYP3A4 inhibitor **Cytochrome P450 3A4****inhibitor:** [SVM model](#)[built on 7518 molecules](#)[\(training set\)](#)


and tested on 2579 No

[molecules \(test set\)](#)

10-fold CV: ACC=0.77 /

[AUC=0.85](#)

External: ACC=0.78 /


[AUC=0.86](#)Log K_p (skin permeation) **Skin permeation:**[QSPR model](#)

-10.28 cm/s

implemented from

[Potts RO and Guy RH.](#)[1992 Pharm. Res.](#)

Druglikeness

Lipinski **Lipinski (Pfizer) filter:**

implemented from

[Lipinski CA. et al. 2001](#)[Adv. Drug Deliv. Rev.](#)

Yes; 0 violation

[MW < 500](#)[MLOGP < 4.15](#)[N or O < 10](#)[NH or OH < 5](#)Ghose **Ghose filter:**

implemented from

[Ghose AK. et al. 1999 J.](#)[Comb. Chem.](#)

No; 3 violations: WLOGP<-0.4,

MR<40, #atoms<20

[160 < MW < 480](#)[-0.4 < WLOGP < 5.6](#)[40 < MR < 130](#)[20 < atoms < 70](#)Veber **Veber (GSK) filter:**

implemented from

[Veber DF. et al. 2002 J.](#)[Med. Chem.](#)

Yes



[Rotatable bonds < 10](#)[TPSA < 140](#)Egan **Egan (Pharmacia)****filter:** implemented

from

[Egan WJ. et al. 2000 J.](#)[Med. Chem.](#)

Yes

[WLOGP < 5.88](#)[TPSA < 131.6](#)

Muegge **Muegge (Bayer) filter:**[implemented from](#)[Muegge I. et al. 2001 J.](#)[Med. Chem.](#)[200 < MW < 600](#)[-2 < XLOGP < 5](#)[TPSA < 150](#)[Num. rings < 7](#)[Num. carbon > 4](#)[Num. heteroatoms > 1](#)[Num. rotatable bonds <](#)[15](#)[H-bond acc. < 10](#)[H-bond don. < 5](#)No; 2 violations: MW<200,
XLOGP3<-2Bioavailability Score **Abbott Bioavailability****Score: Probability of F**[> 10% in rat](#)

0.55

[implemented from](#)[Martin YC. 2005 J.](#)[Med. Chem.](#)

Medicinal Chemistry

PAINS **Pan Assay Interference****Structures:**[implemented from](#)


0 alert

[Baell JB. & Holloway](#)[GA. 2010 J. Med.](#)[Chem.](#)Brenk **Structural Alert:**[implemented from](#)

0 alert

[Brenk R. et al. 2008](#)[ChemMedChem](#)Leadlikeness **Leadlikeness:**[implemented from](#)[Teague SJ. 1999 Angew.](#)[Chem. Int. Ed.](#)

No; 1 violation: MW<250

[250 < MW < 350](#)[XLOGP < 3.5](#)[Num. rotatable bonds <](#)[7](#)Synthetic accessibility **Synthetic accessibility****score: from 1 (very****easy) to 10 (very****difficult)****based on 1024****fragmental contributions** 3.42**(FP2) modulated by size****and complexity penalties,****trained on 12'782'590****molecules and tested on****40 external molecules****($r^2 = 0.94$)**